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Background
The purpose of this paper is to provide more complete
explanations of each of the Reporting Recommendations for
Tumor Marker Prognostic Studies (REMARK) checklist items and
to provide specific examples of good reporting drawn from the
published literature. The initial REMARK paper [1–7] recom-
mended items that should be reported in all published tumor
marker prognostic studies (Table 1). The recommendations were
developed by a committee initially convened under the auspices of
the National Cancer Institute and the European Organisation for
Research and Treatment of Cancer. They were based on the
rationale that more transparent and complete reporting of studies
would enable others to better judge the usefulness of the data and to
interpret the study results in the appropriate context. Similar
explanation and elaboration papers had been written to accompany
other reporting guidelines [8–11]. No changes to the REMARK
checklist items are being suggested here. We hope that the current
paper will serve an educational role and lead to more effective
implementation of the REMARK recommendations, resulting in
more consistent, high quality reporting of tumor marker studies.
Our intent is to explain how to properly report prognostic marker
research, not to specify how to perform the research. However, we
believe that fundamental to an appreciation of the importance of
good reportingisabasicunderstandingofhow variousfactorssuchas
specimen selection, marker assay methodology, and statistical study
design and analysis can lead to different study results and
interpretations. Many authors have discussed the factthat widespread
methodological and reporting deficiencies plague the prognostic
literaturein cancer and other specialties [12–21]. Careful reporting of
what was done and what results were obtained allows for better
assessment of study quality and greater understanding of the
relevance of the study conclusions. When available, we have cited
published studies presenting empirical evidence of the quality of
reporting of the information requested by the checklist items.
We recognize that tumor marker studies are generally
collaborative efforts among researchers from a variety of
disciplines. The current paper covers a wide range of topics and
readers representing different disciplines may find certain parts of
the paper more accessible than other parts. Nonetheless, it is
helpful if all involved have a basic understanding of the collective
obligations of the study team.
We have attempted to minimize distractions from more highly
technical material by the use of boxes with supplementary
information. The boxes are intended to help readers refresh their
memories about some theoretical points or be quickly informed
about technical background details. A full understanding of these
points may require studying the cited references.
We aimed to provide a comprehensive overview that not only
educates on good reporting but provides a valuable reference for
the many issues to consider when designing, conducting and
analyzing tumor marker studies. Each item is accompanied by one
or more examples of good reporting drawn from the published
literature. We hope that readers will find the paper useful not only
when they are reporting their studies but also when they are
planning their studies and analyzing their study data.
This paper is structured as the original checklist, according to
the typical sections of scientific reports: Introduction, Materials
and Methods, Results, and Discussion. There are numerous
instances of cross-referencing between sections reflecting the fact
that the sections are interrelated; for example, one must speak
about the analysis methods used in order to discuss presentation of
results obtained using those methods. These cross-references do
not represent redundancies in the material presented and readers
are reminded that distinctions in focus and emphasis between
different items will sometimes be subtle.
One suggestion in the REMARK checklist is to include a
diagram showing the flow of patients through the study (see Item
12). We elaborate upon that idea in the current paper. The flow
diagram is an important element of the Consolidated Standards of
Reporting Trials (CONSORT) Statement, which was developed
to improve reporting of randomized controlled trials (RCTs)
[8,22,23]. Many papers reporting randomized trial results present
a flow diagram showing numbers of patients registered and
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treatment arms, and numbers analyzed. Flow diagrams are also
recommended in the Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) Statement for reporting
observational studies, including cohort studies [9]. A diagram
would indeed be useful for prognostic studies to clarify the
numbers and characteristics of patients included at each stage of
the study. There are additional key aspects of prognostic studies
that need to be reported and would benefit from standardized
presentation. Accordingly we have developed a ‘REMARK
profile’ as a proposed format for describing succinctly key aspects
of the design and analysis of a prognostic marker study; we discuss
the profile in detail in Item 12 below.
The original scope of the REMARK recommendations focused
on studies of prognostic tumor markers that reported measure-
ment of biological molecules found in tissues, blood, and other
body fluids. The recommendations also apply more generally to
prognostic factors other than biological molecules that are often
assessed in cancer patients, including the size of the tumor,
abnormal features of the cells, the presence of tumor cells in
regional lymph nodes, age, and gender among others. Prognostic
research includes study of the wide variety of indicators that help
clinicians predict the course of a patient’s disease in the context of
standard care. REMARK generally applies to any studies
involving prognostic factors, whether those prognostic factors are
biological markers, imaging assessments, clinical assessments, or
measures of functional status in activities of daily living.
REMARK applies to other diseases in addition to cancer. The
processes of measuring and reporting the prognostic factors may
differ, but the same study reporting principles apply.
We suggest that most of the recommendations also apply to
studies looking at the usefulness of a marker for the prediction
of benefit from therapy (typically called a predictive marker in
oncology). Traditionally, predictive markers are evaluated by
determination of whether the benefit of the treatment of
interest compared to another standard treatment depends on
the marker status or value. (See also Items 3 and 9 and Box 1.)
A logical corollary to such a finding is that the prognostic value
of that marker depends on the treatment the patient receives;
for this reason, some view predictive markers as a special class
of prognostic markers. Consequently, REMARK items apply to
many aspects of these studies. In the explanations that follow
for each of the checklist items, we attempted to make note of
some special considerations for studies evaluating predictive
markers. We hope that authors who report predictive marker
studies will therefore find our recommendations useful. As
predictive markers are usually eva l u a t e di nr a n d o m i z e dt r i a l s ,
CONSORT [11] will also apply to reporting of predictive
marker studies.
Although REMARK was primarily aimed at the reporting of
studies that have evaluated the prognostic value of a single marker,
the recommendations are substantially relevant to studies inves-
tigating more than one marker, including studies investigating
complex markers that are composed of a few to many components,
such as multivariable classification functions or indices, or are
based on prognostic decision algorithms. These reporting recom-
mendations do not attempt to address reporting of all aspects of
the development or validation of these complex markers, but
several key elements of REMARK do also apply to these
developmental studies. Moreover, once these complex markers
are fully defined, their evaluation in clinical studies is entirely
within the scope of REMARK.
The development of prognostic markers generally involves a
series of studies. These begin with identification of a relationship
between a biological feature (for example, proliferative index or
genetic alteration) and a clinical characteristic or outcome. To
establish a clear and possibly causal relationship, a series of
studies are conducted to address increasingly demanding
hypotheses. The REMARK recommendations attempt to recog-
nize these stages of development. For example, the discussion of
Item 9 acknowledges that sample size determination may not be
under the investigator’s control but recommends that authors
make clear whether there was a calculated sample size or, if not,
consider the impact of the sample size on the reliability of the
findings or precision of estimated effects. We anticipate that more
details will be available in later stage studies, but many of the
recommendations are also applicable to earlier stage studies.
When specific items of information recommended by REMARK
are not available, these situations should be fully acknowledged in
the report so that readers may judge in context whether these
missing elements are critical to study interpretation. Adherence to
these reporting recommendations as much as possible will permit
critical evaluation of the full body of evidence supporting a
marker.
Checklist Items
Discussion and explanation of the 20 items in the REMARK
checklist (Table 1) are presented. For clarity we have split the
discussion of a few items into multiple parts. Each explanation is
preceded by examples from the published literature that illustrate
types of information that are appropriate to address the item. Our
use of an example from a study does not imply that all aspects of
the study were well reported or appropriately conducted. The
example suggests only that this particular item, or a relevant part
of it, was well reported in that study. Some of the quoted examples
have been edited by removing citations or spelling out abbrevi-
ations, and some tables have been simplified.
Each checklist item should be addressed somewhere in a report
even if it can only be addressed by an acknowledgment that the
information is unknown. We do not prescribe a precise location or
order of presentation as this may be dependent upon journal
policies and is best left to the discretion of the authors of the
report. We recognize that authors may address several items in a
single section of text or in a table. In the current paper, we address
reporting of results under a number of separate items to allow us to
explain them clearly and provide examples, not to prescribe a
heading or location. Authors may find it convenient to report some
Summary Points
N The REMARK (Reporting Recommendations for Tumor
Marker Prognostic Studies) guideline includes a checklist
which aims to improve the reporting of these types of
studies.
N Here, we expand on the REMARK checklist to enhance its
use and effectiveness through better understanding of
the intent of each item and why the information is
important to report.
N Each checklist item of the REMARK guideline is explained
in detail and accompanied by published examples of
good reporting.
N The paper provides a comprehensive overview to
educate on good reporting and provide a valuable
reference of issues to consider when designing, con-
ducting, and analyzing tumor marker studies and
prognostic studies in medicine in general.
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example on a journal website, rather than in the body of the
manuscript, to allow sufficient space for adequate detail to be
provided. One strategy that has been used successfully is to
provide the information in a supplementary table organized
according to the order of the REMARK items [24]. The elements
of the supplementary table may either provide the information
directly in succinct form or point the reader to the relevant section
of the main paper where the information can be found. Authors
wishing to supply such a supplementary table with their paper may
find it helpful to use the REMARK reporting template that is
supplied as Text S1; it can also be downloaded from http://www.
Table 1. The REMARK checklist [1–7].
INTRODUCTION
1 State the marker examined, the study objectives, and any pre-specified hypotheses.
MATERIALS AND METHODS
Patients
2 Describe the characteristics (for example, disease stage or co-morbidities) of the study patients, including their source and
inclusion and exclusion criteria.
3 Describe treatments received and how chosen (for example, randomized or rule-based).
Specimen characteristics
4 Describe type of biological material used (including control samples) and methods of preservation and storage.
Assay methods
5 Specify the assay method used and provide (or reference) a detailed protocol, including specific reagents or kits used, quality
control procedures, reproducibility assessments, quantitation methods, and scoring and reporting protocols. Specify whether and
how assays were performed blinded to the study endpoint.
Study design
6 State the method of case selection, including whether prospective or retrospective and whether stratification or matching (for
example, by stage of disease or age) was used. Specify the time period from which cases were taken, the end of the follow-up
period, and the median follow-up time.
7 Precisely define all clinical endpoints examined.
8 List all candidate variables initially examined or considered for inclusion in models.
9 Give rationale for sample size; if the study was designed to detect a specified effect size, give the target power and effect size.
Statistical analysis methods
10 Specify all statistical methods, including details of any variable selection procedures and other model-building issues, how model
assumptions were verified, and how missing data were handled.
11 Clarify how marker values were handled in the analyses; if relevant, describe methods used for cutpoint determination.
RESULTS
Data
12 Describe the flow of patients through the study, including the number of patients included in each stage of the analysis (a diagram
may be helpful) and reasons for dropout. Specifically, both overall and for each subgroup extensively examined report the number
of patients and the number of events.
13 Report distributions of basic demographic characteristics (at least age and sex), standard (disease-specific) prognostic variables,
and tumor marker, including numbers of missing values.
Analysis and presentation
14 Show the relation of the marker to standard prognostic variables.
15 Present univariable analyses showing the relation between the marker and outcome, with the estimated effect (for example,
hazard ratio and survival probability). Preferably provide similar analyses for all other variables being analyzed. For the effect of a
tumor marker on a time-to-event outcome, a Kaplan-Meier plot is recommended.
16 For key multivariable analyses, report estimated effects (for example, hazard ratio) with confidence intervals for the marker and, at
least for the final model, all other variables in the model.
17 Among reported results, provide estimated effects with confidence intervals from an analysis in which the marker and standard
prognostic variables are included, regardless of their statistical significance.
18 If done, report results of further investigations, such as checking assumptions, sensitivity analyses, and internal validation.
DISCUSSION
19 Interpret the results in the context of the pre-specified hypotheses and other relevant studies; include a discussion of limitations of
the study.
20 Discuss implications for future research and clinical value.
Note: we have changed ‘univariate’ to ‘univariable’ in item 15 for consistency with ‘multivariable’.
doi:10.1371/journal.pmed.1001216.t001
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reporting/reporting-guidelines/remark.
Introduction
Item 1. State the marker examined, the study objec-
tives, and any pre-specified hypotheses.
Examples
Marker examined:
‘Using the same cohort of patients, we investigated the
relationship between the type, density, and location of immune
cells within tumors and the clinical outcome of the patients.’ [25]
Objectives:
‘The purpose of this study was to determine whether CpG
island hypermethylation in the promoter region of the APC gene
occurs in primary esophageal carcinomas and premalignant
lesions, whether freely circulating hypermethylated APC DNA is
detectable in the plasma of these patients, and whether the
presence and quantity of hypermethylated APC in the plasma
have any relationship with outcome.’ [26]
‘The goal of this study was to develop a sensitive and specific
method for CTC [circulating tumor cell] detection in HER-2-
positive breast cancer, and to validate its ability to track disease
response and progression during therapy.’ [27]
Hypotheses:
‘The prespecified hypotheses tested were that TS expression
level and p53 expression status are markers of overall survival (OS)
in potentially curatively resected CRC.’ [28]
Explanation
Clear indication of the particular markers to be examined, the
study objectives, and any pre-specified hypotheses should be
provided early in the study report. Objectives are goals one hopes
to accomplish by conducting the study. Typical objectives for tumor
marker prognostic studies include, among others, an evaluation of
the association between tumor marker value and clinical outcome,
or determination of whether a tumor marker contributes additional
information about likely clinical outcome beyond the information
provided by standard clinical or pathologic factors.
The description of the marker should include both the biological
aspects of the marker as well as the time in a patient’s clinical
course when it is to be assessed. The biological aspects should
include the type of molecule or structure examined (for example,
protein, RNA, DNA, or chromosomes) and the features assessed
(for example, expression level, copy number, mutation, or
translocation). Most prognostic marker studies are performed on
specimens obtained at the time of initial diagnosis. The marker
could also be assessed on specimens collected at completion of an
initial course of therapy (for example, detection of minimal
residual disease or circulating tumor cells to predict recurrence or
progression) or at the time of recurrence or progression. A
thorough description of the marker and timing of specimen
collection is necessary for an understanding of the biological
rationale and potential clinical application.
The stated objectives often lead to the development of specific
hypotheses. Hypotheses should be formulated in terms of measures
that are amenable to statistical evaluation. They represent
Box 1. Subgroups and Interactions: The Analysis of Joint Effects
Itisoftenofinteresttoconsiderwhethertheeffectofamarker
differs in relation to a baseline variable, which may be
categorical or continuous. Categorical variables, such as stage
of disease, naturally define subgroups and continuous
variables are often categorized by using one or more
cutpoints. Investigating whether the marker effect is different
(modified) in subgroups is popular. Epidemiologists speak
about effect modification; more generally this phenomenon
refers to the interaction between two variables.
In the context of randomized trials, one of these variables is
the treatment and the other variable defines subgroups of the
population. Here the interaction between treatment and the
marker indicates whether the marker is predictive of treat-
ment effect (that is, a predictive marker) [185]. This analysis is
easiest for a binary marker. Subgroup analyses are often
conducted. The interpretation of their results depends
critically on whether the subgroup analyses were pre-
specified or conducted post hoc based on results seen in the
data. Subgroup differences are far more convincing when
such an effect had been postulated; unanticipated significant
effects are more likely to be chance findings and should be
interpreted as being interesting hypotheses needing confir-
mation from similar trials. The same principles apply to
consideration of subgroups in prognostic marker studies.
Subgroup analyses need to be done properly and interpreted
cautiously. It is common practice to calculate separate P
values for the prognostic effect of the marker in separate
subgroups,oftenfollowed byan erroneous judgment that the
marker has an effect in one subgroup but not in the other.
However, a significant effect in one group and a non-
significant effect in the other is not sound evidence that the
effect of the marker differs by subgroup [186,187]. First, a
single test of interaction is required to rigorously assess
whether effects are different in subgroups [188]. Interactions
between two variables are usually investigated by testing the
multiplicative term for significance (for example, in a Cox
model). In many studies the sample size is too small to allow
the detection of other than very large (and arguably
implausible) interaction effects [189]. If the test of interaction
is significant, then further evaluation may be required to
determinethe nature of the interaction, particularly whether it
is qualitative (effects in opposite directions) or quantitative
(effects in same direction but differing in magnitude). Because
of the risk of false positive findings, replication is critical [190].
For continuous variables, categorization is a popular
approach, but it has many disadvantages: the results depend
on the chosen cutpoints (see Item 11 and Box 4), and it
reduces the power to detect associations between marker
variables and outcome [191]. The multivariable fractional
polynomial interaction approach is an alternative that uses
full information from the data and avoids specification of
cutpoints. It allows investigation of interactions between a
binary and a continuous variable, with or without adjust-
ment for other variables [191,192].
Another approach to assess the effect of treatment in
relation to a continuous variable is the Subpopulation
Treatment Effect Pattern Plot [193].
Both approaches were developed in the context of random-
ized trials, but they readily apply to observational prognostic
studies investigating the interaction of a continuous marker
with a binary or a categorical variable such as sex or stage
[110,194].
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results of the study. An example of a hypothesis is ‘high expression
levels of the protein measured in the tumor at the time of diagnosis
are associated with shorter disease-free survival’.
Pre-specified hypotheses are those that are based on prior
research or an understanding of a biological mechanism, and they
are stated before the study is initiated. Ideally, a systematic review
of the literature should have been performed. New hypotheses
may be suggested by inspection of data generated in the study.
Analyses performed to address the new hypotheses are exploratory
and should be reported as such. The distinction between analysis
of the pre-specified hypotheses and exploratory analyses is
important because it affects the interpretation (see Item 19) [9].
Materials and Methods
Patients
Item 2. Describe the characteristics (for example,
disease stage or co-morbidities) of the study patients,
including their source and inclusion and exclusion
criteria.
Examples
‘Inclusion criteria for the 2810 patients from whom tumour or
cytosol samples were stored in our tumour bank (liquid nitrogen)
were: primary diagnosis of breast cancer between 1978 and 1992
(at least 5 years of potential follow-up); no metastatic disease at
diagnosis; no previous diagnosis of carcinoma, with the exception
of basal cell skin carcinoma and cervical cancer stage I; no
evidence of disease within 1 month of primary surgery … Patients
with inoperable T4 tumours and patients who received neoadju-
vant treatment before primary surgery were excluded.’ [29]
‘We studied 196 adults who were younger than 60 years and
who had untreated primary CN-AML. The diagnosis of CN-AML
was based on standard cytogenetic analysis that was performed by
CALGB-approved institutional cytogenetic laboratories as part of
the cytogenetic companion study 8461. To be considered
cytogenetically normal, at least 20 metaphase cells from diagnostic
bone marrow (BM) had to be evaluated, and the karyotype had to
be found normal in each patient. All cytogenetic results were
confirmed by central karyotype review. All patients were enrolled
on two similar CALGB treatment protocols (i.e., 9621 or 19808).’
[30]
‘These analyses were conducted within the context of a
completed clinical trial for breast cancer (S8897), which was led
by SWOG within the North American Breast Cancer Intergroup
(INT0102) … Complete details of S8897 have been reported
elsewhere [citation].’ [31]
Relevant text in the reference cited by Choi et al. [31]: ‘Patients
were registered from the Southwest Oncology Group, Eastern
Cooperative Oncology Group, and Cancer and Leukemia Group
B … Eligible patients included premenopausal and postmeno-
pausal women with T1 to T3a node negative invasive adenocar-
cinoma of the breast.’ [32]
Explanation
Each prognostic factor study includes data from patients drawn
from a specific population. A description of that population is
needed to place the study in a clinical context. The source of the
patients should be specified, for example from a clinical trial
population, a healthcare system, a clinical practice, or all hospitals
in a certain geographic area.
Patient eligibility criteria, usually based on clinical or pathologic
characteristics, should be clearly stated. As a minimum, eligibility
criteria should specify the site and stage of cancer of the cases to be
studied. Stage is particularly important because many tumor
markers have prognostic value in early stage disease but not in
advanced stage disease. For example, if a marker is indicative of
metastatic potential, it may have strong prognostic value in
patients with early stage disease but be less informative for patients
who already have advanced or metastatic disease. For this reason,
many studies are restricted to certain stages. Additional selection
criteria may relate to factors such as patient age, treatment
received (see Item 3), or the histologic type of cancer.
Exclusion criteria might be factors such as prior cancer, prior
systemic treatment for cancer, nonstandard treatment (for
example, rarely used, non-approved or ‘off-label’ use of a therapy),
failure to obtain informed consent, insufficient tumor specimen, or
a high proportion of missing critical clinical or pathologic data. It
is generally not appropriate to exclude a case just because it has a
few missing data elements if those data elements are not critical for
assessment of primary inclusion or exclusion criteria (see Item 6a)
[33]. In some studies, deaths that have occurred very early after
the initiation of follow-up are excluded. If this is done, the
rationale and timeframe for exclusion should be specified. To the
extent possible, exclusion criteria should be specified prior to
initiation of the study to avoid potential bias introduced by
exclusions that could be partly motivated by intermediate analysis
results.
When a prognostic study is performed using a subset of cases
from a prior ‘parent’ study (for example, from a RCT or a large
observational study cohort), there may be a prior publication or
other publicly available document such as a study protocol that
lists detailed eligibility and inclusion and exclusion criteria for the
parent study. In these cases, the prior document can be referenced
rather than repeating all of the details in the prognostic study
paper. However, it is preferable that at least the major criteria (for
example, the site and stage of the cancer) for the parent study still
be mentioned in the prognostic study paper, and it is essential that
any additional criteria imposed specifically for the prognostic study
(such as availability of adequate specimens) be stated in the
prognostic study paper.
Specification of inclusion and exclusion criteria can be
especially challenging when the study is conducted retrospectively.
The real population that the cases represent is often unclear if the
starting point is all cases with accessible medical records or all
cases with specimens included in a tumor bank. A review of 96
prognostic studies found that 40 had the availability of tumor
specimens or data as an inclusion criterion [33]. In some studies,
unknown characteristics may have governed whether cases were
represented in the medical record system or tumor bank, making it
impossible to specify exact inclusion and exclusion criteria. If the
specimen set was assembled primarily on the basis of ready
availability (that is, a ‘convenience’ sample), this should be
acknowledged.
A flow diagram is very useful for succinctly describing the
characteristics of the study patients. The entrance point to the flow
diagram is the source of patients and successive steps in the
diagram can represent inclusion and exclusion criteria. Some of
the information from this diagram can also be given in the upper
part of the REMARK profile (see Item 12 for examples).
After the study population has been defined, it is important to
describe how the specific cases included in the study were sampled
from that population. Item 6a discusses reporting of case selection
methods.
Item 3. Describe treatments received and how cho-
sen (for example, randomized or rule-based).
Examples
‘Patients were treated with surgery by either modified radical
mastectomy (637 cases) or local tumour resection (683 cases), with
PLoS Medicine | www.plosmedicine.org 5 May 2012 | Volume 9 | Issue 5 | e1001216axillary node dissection followed by postoperative breast irradia-
tion (695 cases). Adjuvant therapy with chemotherapy and/or
hormone therapy was decided according to nodal status and
hormone receptor results. Treatment protocols varied over time.
From 1975 to 1985, node-negative patients had no chemotherapy.
After 1985, node-negative patients under 50 years of age, with ER
and PR negative and SBR [Scarff-Bloom-Richardson] grade 3
tumours, had chemotherapy.’ [34]
‘Details of the treatment protocols have been previously
reported. Briefly, patients on CALGB 9621 received induction
chemotherapy with cytarabine, daunorubicin, and etoposide with
(ADEP) or without (ADE) the multidrug resistance protein
modulator PSC-833, also called valspodar. Patients who had
CN-AML and who achieved a CR received high-dose cytarabine
(HiDAC) and etoposide for stem-cell mobilization followed by
myeloablative treatment with busulfan and etoposide supported by
APBSCT. Patients unable to receive APBSCT received two
additional cycles of Hi-DAC. Patients enrolled on CALGB 19808
were treated similarly to those on CALGB 9621. None of the
patients received allogeneic stem-cell transplantation in first
remission.’ [30]
Explanation
A patient’s disease-related clinical outcome is determined by a
combination of the inherent biological aggressiveness of a patient’s
tumor and the response to any therapies received. The influence of
biological characteristics on disease outcome would ideally be
assessed in patients who received no treatment, but usually most
patients will have received some therapy. Many patients with solid
tumors will receive local-regional therapy (for example, surgery
and possibly radiotherapy). For some types and stages of cancer,
patients would almost always receive systemic therapy (for
example, chemotherapy or endocrine therapy). Sometimes all
patients included in a study will have received a standardized
therapy, but more often there will be a mix of treatments that
patients have received. The varied treatments that patients might
receive in standard care settings can make study of prognostic
markers especially challenging.
Because different treatments might alter the disease course in
different ways, it is important to report what treatments the
patients received. The impact of a treatment might also depend
on the biological characteristics of the tumor. This is the essence
of predictive marker research where the goal is to identify the
treatment that leads to the best clinical outcome for each
biological class of tumor (for example, defined by markers) (see
Box 1).
The basis for treatment selection, if known, should be reported.
If not known, as will often be the case for retrospective specimen
collections, one must be cautious in interpreting prognostic and
predictive analyses. This concern derives from the possibility that
the value of the marker or patient characteristics associated with
the marker played a role in the choice of therapy, thereby leading
to a potential confounding of effects of treatment and marker. If
sufficient numbers of patients are treated with certain therapies,
assessment of the prognostic value of the marker separately by
treatment group (see Box 1) could be considered. However,
predictive markers should generally be evaluated in randomized
clinical trials to ensure that the choice of treatment was not
influenced by the marker or other biological characteristics of the
tumor.
It is also important to report the timing of therapy relative to
specimen collection since biological characteristics of a tumor
may be altered by the therapies to which it was exposed prior to
specimen collection (see Item 4). The prognostic value of a
marker may be different depending on whether it was present in
the tumor at the time of initial diagnosis, was present only after
the patient received therapy or whether it is in the presence of
other biological characteristics that emerged as a consequence of
therapy.
Specimen Characteristics
Item 4. Describe type of biological material used
(including control samples) and preservation and stor-
age methods.
Examples
Positive and negative controls:
‘Tumor specimens were obtained at the time of surgery and
snap frozen in liquid nitrogen, then stored at 280uC. Blood
samples were collected 24 hours or less before surgery by
peripheral venous puncture and were centrifuged at 15006ga t
4uC for 10 minutes. The separated plasma was aliquoted and
stored at 280uC for future analysis. Normal endometrial tissue
specimens were obtained from patients undergoing hysterectomy
for benign gynecologic pathologies. Control plasma specimens
were derived from health check examinees at Yongdong
Severance Hospital who showed no history of cancer or
gynecologic disease and had no abnormalities in laboratory
examinations or gynecologic sonography.’ [35]
Preservation and storage methods:
‘Fixation of tumor specimens followed standard protocols, using
either 10% nonbuffered or 10% buffered formalin for 12 hours.
Storage time of the archival samples was up to 15 years. Of the 57
independent MCL cases, 42 tumors had amplifiable cDNA.’ [36]
‘Tissue samples were fixed in 10% buffered formalin for 24 h,
dehydrated in 70% EtOH and paraffin embedded. Five micro-
meter sections were cut using a cryostat (Leica Microsystems, UK)
and mounted onto a histological glass slide. Ffpe [formalin-fixed,
paraffin-embedded] tissue sections were stored at room temper-
ature until further analysis.’ [37]
Explanation
Most tumor marker prognostic studies have focused on one or
more of the following types of specimens: tumor tissue (formalin
fixed and paraffin-embedded or frozen); tumor cells or tumor
DNA isolated from blood, bone marrow, urine, or sputum; serum;
or plasma. Authors should report what types of specimens were
used for the marker assays. As much information about the source
of the specimen as possible should be included, for example,
whether a tumor sample was obtained at the time of definitive
surgery or from a biopsy procedure such as core needle biopsy or
fine needle aspirate. For patients with advanced disease, it should
be clearly stated whether tumor samples assayed came from the
primary tumor site (perhaps collected years earlier at the time of
an original diagnosis of early stage disease) or from a current
metastatic lesion and whether the patient had been exposed to any
prior cancer-directed therapies (see Item 3).
Much has been written about the potential confounding effects
of pre-analytical handling of specimens, and several organizations
have recently published articles addressing best practices for
specimen handling [38–40]. Although the way specimens are
collected is often not under the control of investigators studying
prognostic markers, it is important to report as much as possible
about the types of biological materials used in the study and the
way these materials were collected, processed, and stored. The
time of specimen collection will often not coincide with the time
when the marker assay is performed, as it is common for marker
assays to be performed after the specimens have been stored for
some period of time. It is important to state how long and how the
specimens had been stored prior to performing the marker assay.
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(BRISQ) guidelines provide comprehensive recommendations for
what information should be reported regarding specimen charac-
teristics and methods of specimen processing and handling when
publishing research involving the use of biospecimens [41]. It is
understood that reporting extensive detail is difficult if not
impossible, especially when retrospective collections are used. In
recognition of these difficulties, the BRISQ guidelines are
presented in three tiers, according to the relative importance
and feasibility of reporting certain types of biospecimen informa-
tion.
Criteria for acceptability of biospecimens for use in marker
studies should be established prior to initiating the study.
Depending on the type of specimen and particular assay to be
performed, criteria could be based on metrics such as percentage
tumor cellularity, RNA integrity number, percentage viable cells,
or hemolysis assessment. These criteria should be reported along
with a record of the percentage of specimens that met the criteria
and therefore were included in the study. The numbers of
specimens examined at each stage in the study should be recorded
in the suggested flowchart and, particularly, in the REMARK
profile (see Item 12). This information permits the reader to better
assess the feasibility of collecting the required specimens and might
indicate potential biases introduced by the specimen screening
criteria.
Often, the specific handling of a particular set of specimens may
not be known, but if the standard operating procedures of the
pathology department are known, it is helpful to report
information such as type of fixative used and approximate length
of fixation time; both fixative and fixation time have been reported
to dramatically affect the expression of some markers evaluated in
tissue [42,43].
Information should be provided about whether tissue sections
were cut from a block immediately prior to assaying for the
marker. If tissue sections have been stored, the storage conditions
(for example, temperature and air exposure) should be noted, if
known. Some markers assessed by immunohistochemistry have
shown significant loss of antigenicity when measured in cut
sections that had been stored for various periods of time [44,45].
The use of stabilizers (for example, to protect the integrity of RNA)
should be reported. For frozen specimens, it is important to report
how long they were stored, at what temperature and whether they
had been thawed and re-frozen. If the specimen studied is serum
or plasma, information should be provided about how the
specimen was collected, including anticoagulants used, the
temperature at which the specimen was maintained prior to
long-term storage, processing protocols, preservatives used, and
conditions of long-term storage.
Typically, some control samples will be assayed as part of the
study. Control samples may provide information about the marker
in non-diseased individuals (biological controls) or they may
provide a means to monitor assay performance (assay controls).
Biological control samples may be obtained from healthy
volunteers or from other patients visiting a clinic for medical care
unrelated to cancer. Apparently normal tissue adjacent to the
tumor tissue (in the same section) may be used or normal tissue
taken during the surgical procedure but preserved in a separate
block may also be used as a control. It is important to discuss the
source of the biological controls and their suitability with respect to
any factors that might differ between the control subjects and
cancer patients (for example, other morbidities and medications,
sex, age, and fasting status) and have an impact on the marker
[46]. Information about the comparability of handling of control
samples should also be provided.
Information about assay control or calibrator samples should
also be reported. For example, if dilution series are used to
calibrate daily assay runs or control samples with known marker
values are run with each assay batch, information about these
samples should be provided (see Item 5).
Assay Methods
Item 5. Specify the assay method used and provide
(or reference) a detailed protocol, including specific
reagents or kits used, quality control procedures,
reproducibility assessments, quantitation methods,
and scoring and reporting protocols. Specify whether
and how assays were performed blinded to the study
endpoint.
Examples
‘Immunohistochemistry was used to detect the presence of p27,
MLH1, and MSH2 proteins in primary tumor specimens using
methods described in previous reports. Positive controls were
provided by examining staining of normal colonic mucosa from
each case; tumors known to lack p27, MLH1, or MSH2 were
stained concurrently and served as negative controls … In this
report, we scored the tumors using a modification of our previous
methods that we believe provides best reproducibility and yields
the same outcome result as that using our previous scoring method
(data not shown). Nuclear expression of p27 was evaluated in a
total of 10 randomly selected high-power fields per tumor. A
tumor cell was counted as p27 positive when its nuclear reaction
was equal to or stronger than the reaction in surrounding
lymphocytes, which were used as an internal control. All cases
were scored as positive (.10% of tumor cells with strong nuclear
staining), negative (,10% of tumor cells with strong nuclear
staining), or noninformative.’ [47]
‘Evaluation of immunostaining was independently performed
by two observers (KAH and PDG), blinded to clinical data. The
agreement between the two observers was .90%. Discordant
cases were reviewed with a gynaecological pathologist and were re-
assigned on consensus of opinion.’ [48]
Explanation
Assay methods should be reported in a complete and
transparent fashion with a level of detail that would enable
another laboratory to reproduce the measurement technique. The
term ‘assay’ is used broadly to mean any measurement process
applied to a biological specimen that yields information about that
specimen. For example, the assay may involve a single biochemical
measurement or multiple measurements, or it may involve a semi-
quantitative and possibly subjective scoring based on pathologic
assessment. It has been demonstrated for many markers that
different measurement techniques can produce systematically
different results. For example, different levels of human epidermal
growth factor receptor 2 expression have been found using
different methods [49,50]. Variations of p53 expression were
observed in bladder tumors due to different staining techniques
and scoring methods in a reproducibility study comparing
immunohistochemical assessments performed in five different
laboratories [51].
Although a complete listing of the relevant information to report
for every class of assay is beyond the scope of this paper, examples
of the general types of technical details that should be reported are
as follows. Specific antibodies, antigen retrieval steps, standards
and reference materials, scoring protocol, and score reporting and
interpretation (for example, if results are reported as positive or
negative) should be described for immunohistochemical assays.
For DNA- and RNA-based assays, specific primers and probes
should be identified along with any scoring or quantitation
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published paper) details the exact assay method used, it is
acceptable to reference that other document without repeating
all the technical details. If a commercially available kit is used for
the assay, it is important to state whether the kit instructions were
followed exactly; any deviations from the kit’s recommended
procedures must be fully acknowledged in the report.
It is important to report the minimum amount of specimen that
was required to perform the assay (for example, a 5 mm section or
5 mg DNA) and whether there were any other assessments that
were performed to judge the suitability of the specimen for use in
the study (see Item 4). Assays requiring a large amount of specimen
may not be feasible for broader clinical application, and study
results may be biased toward larger tumors. If there were any
additional specimen pre-processing steps required (for example,
microdissection or polymerase chain reaction amplification), these
should be stated as well.
It is helpful to report any procedures, such as use of blinded
replicate samples or control reference samples, that are employed
to assess or promote consistency of assay results over time or
between laboratory sites. For assays in a more advanced state of
development, additional examples could include qualification
criteria for new lots of antibodies or quantitative instrument
calibration procedures. If reproducibility assessments have been
performed, it is helpful to report the results of those studies to
provide a sense of the overall variability in the assay and identify
major sources contributing to the variability.
Despite complete standardization of the assay technique and
quality monitoring, random variation (measurement error) in assay
results may persist due to assay imprecision, variation between
observers or intratumoral biological heterogeneity. For example,
many immunohistochemical assays require selection of ‘best’ regions
to score, and subjective assessments of staining intensity and
percentage of stained cells. The impact of measurement error is
attenuation of the estimated prognostic effect of the marker. Good
prognostic performance of a marker cannot be achieved in the
presence of a large amount of imprecision. It is important to report
any strategies that were employed to reduce the measurement error,
such as taking the average of two or three readings to produce a
measurement with less error, potentially increasing the power of the
study and hence the reliability of the findings. In multicenter studies,
single reviewers or reference laboratories are often used to reduce
variabilityinmarkermeasurements,andsucheffortsshouldbenoted.
There may be a risk of introducing bias when a patient’s clinical
outcome is known by the individual making the marker assessment,
particularly when the marker evaluation involves considerable
subjective judgment. Therefore, it is important to report whether
marker assessments were made blinded to clinical outcome.
Study Design
Item 6. State the method of case selection, including
whether prospective or retrospective and whether strat-
ification or matching (for example, by stage of disease
or age) was used. Specify the time period from which
cases were taken, the end of the follow-up period, and
the median follow-up time.
To clarify the discussion we have split this item into two parts.
a. Case selection
Examples
‘We retrospectively analysed tumour samples from patients who
were prospectively enrolled in phase II and III trials of HDC for
HRPBC at the University of Colorado between 1990 and 2001.’
[52]
‘Seven hundred and seventy female patients with primary
invasive breast cancer, diagnosed between 1992 and 1997 at the
Institute of Oncology, Ljubljana, were included in the study. The
patients had not been previously treated, had no proven metastatic
disease at the time of diagnosis and no synchronous or
metachronous occurring cancer. The primary inclusion criterion
was an adequate histogram obtained from an FNA sample (see
below). The diagnosis of carcinoma was therefore first established
by FNA and subsequently confirmed and specified by histological
examination in 690 primarily resected tumours (80 patients were
not treated surgically).’ [53]
‘Of the 165 patients, all patients who had a pathology report of
a non-well-differentiated (defined as moderately- to poorly-
differentiated) SCC were identified. A matched control group of
well-differentiated SCC was identified within the database.
Matching criteria were (1) age (65 y), (2) gender, and (3) site.’ [54]
Explanation
The reliability of a study depends importantly on the study
design. An explanation of how patients were selected for inclusion
in the study should be provided. Reliance on a label of
‘prospective’ or ‘retrospective’ is inadequate because these terms
are ill-defined [55]. It should be clearly stated whether patients
were recruited prospectively as part of a planned marker study,
represent the full set or a subset of patients recruited prospectively
for some other purpose such as a clinical trial, or were identified
retrospectively through a search of an existing database, for
example from hospital or registry records or from a tumor bank.
Whether patients were selected with stratification according to
clinicopathologic factors such as stage, based on survival
experience or according to a matched design (for example,
matched pairs of patients who did and did not recur) has
important implications for the analysis and interpretation, so
details of the procedures used should be reported.
Authors should describe exactly how and when clinical,
pathologic, and follow-up data were collected for the identified
patients. Itshould be statedwhetherthemarker measurements were
extracted retrospectively from existing records, whether assays were
newly performed using stored specimens, or whether assays were
performed in real time using prospectively collected specimens.
In truly prospective studies, complete baseline measurements
(marker or clinicopathologic factors) can be made according to a
detailed protocol using standard operating procedures, and the
patients can be followed for an adequate length of time to allow a
comparison of survival and other outcomes in relation to baseline
tumor marker values. Prospective patient identification and data
collection are preferable because the data will be higher quality.
Prospective studies specifically designed to address marker
questions are rare, although some prognostic studies are embed-
ded within randomized treatment trials. Aside from a potential
sample size problem, a prognostic marker study may be restricted
to only some of the centers from a multicenter RCT. Case
selection within participating centers (for example, inclusion of
only younger patients or those with large tumors) may introduce
bias and details of any such selection should be reported.
Most prognostic factor studies are retrospective in the sense that
the assay of interest is performed on stored samples. The benefit of
these retrospective studies is that there is existing information about
moderate or long-term patient follow-up. Their main disadvantage
is the lower quality of the data - clinical information collected
retrospectively is often incomplete and clinicopathologic data may
not have been collected in a standardized fashion (except perhaps if
the data were collected as part of a clinical trial). Eligible patients
shouldbeconsideredtobepartofthestudycohortand not excluded
because of incomplete data or loss to follow-up, with the amount of
PLoS Medicine | www.plosmedicine.org 8 May 2012 | Volume 9 | Issue 5 | e1001216missing data reported for each variable. That allows readers to
judge the representativeness of the patients whose data were
available for analysis. (See also Item 10e, Item 12, and Box 2.)
In situations where more complex case selection strategies are
used, those approaches must be carefully described. Given the small
size of most prognostic studies (see Item 9), it is sometimes desirable
to perform stratified sampling to ensure that important subgroups
(for example, different stages of disease or different age groups) are
represented. The stratified sampling may be in proportion to the
prevalences of the subgroups in the population, or more rare
subgroups may be oversampled (weighted with a higher sampling
probability), especially if subgroup analyses are planned.
Occasionally, patients are sampled in relation to their survival
experience - for example, taking only patients with either very
short or very long survival (excluding some patients who were
censored). Simulation studies have shown that sampling which
excludes certain subgroups of patients leads to bias in estimates of
prognostic value and thus should be avoided [56]. If a large
number of patients is available for study but few patients had
events, case-control (a case being a patient with an event, a control
being a patient without an event) sampling methods (matched or
unmatched) may offer improved efficiency.
If standard survival analysis methods are used, unselected cases
or random samples of cases from a given population are necessary
to produce unbiased survival estimates. If more complex stratified,
weighted, or case-control sampling strategies are used, then
specialized analysis methods appropriate for those sampling
designs (for example, stratified and weighted analyses or condi-
tional logistic regression) should have been applied and should be
described [57,58] (see Item 10).
b. Time period
Examples
‘… 1143 primary invasive breast tumors collected between 1978
and 1989 … All patients were examined routinely every 3–6
months during the first 5 years of follow-up and once a year
thereafter. The median follow-up period of patients alive (n=584)
was 124 months (range, 13–231 months). Patients with events after
120 months were censored at 120 months because after 10 years of
observation, patients frequently are redirected to their general
practitioner for checkups and mammography and cease to visit
our outpatient breast cancer clinic.’ [59]
‘The estimated median follow-up time, as calculated by the
reverse Kaplan-Meier method, was 4.3 years.’ [60]
Explanation
Knowing when a study took place and over what period
participants were recruited places a study in historical context.
Medical and surgical therapies evolve continuously and may affect
the routine care given to patients over time. In most studies where
the outcome is the time to an event, follow-up of all participants is
ended on a specific date. This date should be given, and it is also
useful to report the median duration of follow-up.
The method of calculating the median follow up should be
specified. The preferred approach is the reverse Kaplan-Meier
method, which uses data from all patients in the cohort [61]. Here,
the standard Kaplan-Meier method is used with the event
indicator reversed so that censoring becomes the outcome of
interest. Sometimes it may be helpful to also give the median
follow-up of those patients who did not have the event (in other
words, those with censored survival times). The amount of follow-
up may vary for different endpoints, for example when recurrence
is assessed locally but information about deaths comes from a
central register.
It may also be useful to report how many patients were lost to
follow-up for a long period (for example, over one year) or the
completeness of the data compared to that if no patient was lost to
follow-up [62,63].
In a review of 132 reports in oncology journals in 1991 that used
survival analysis, nearly 80% included the starting and ending
dates for accrual of patients, but only 24% also reported the date
on which follow-up ended [64]. A review of articles published in
2006 found those dates reported in 74% and 18% of articles,
respectively. Of 331 studies included in 20 published meta-
analyses, the time period during which patients were selected was
precisely defined in 232 (70%) [18].
Item 7. Precisely define all clinical endpoints exam-
ined.
Examples
‘Survival time was defined to be the period of time in months
from the date of diagnosis to the date of death from breast cancer.
Patients who died from causes other than those relating to breast
cancer were included for the study, and data for these records were
treated as right-censored cases for evaluation purposes. Relapse
time was defined as the period of time in months from the date of
diagnosis to the date at which relapse was clinically identified.
Data on patients who dropped out of the study for reasons other
than a breast-cancer relapse were considered right-censored for
these analyses.’ [65]
Box 2. Missing Data
Missing data occur in almost all studies. The most common
approach to dealing with missing data is to restrict analyses to
individuals with complete data on all variables required for a
particular analysis. These complete-case analyses can be
biased if individuals with missing data are not typical of the
whole sample. Furthermore, a small number of missing values
in each of several variables can result in a large number of
patients excluded from a multivariable analysis. The smaller
sample size leads to a reduction in statistical power.
Imputation, in which each missing value is replaced with
an estimated value, is a way to include all patients in the
analysis. However, simple forms of imputation (for exam-
ple, replacing values by the stage-specific mean) are likely
to produce standard errors that are too small.
Data are described as missing completely at random (MCAR)
if the probability that a specific observation is missing does
not depend on the value of any observable variables. Data
are missing at random (MAR) if missingness depends only on
other observed variables. Data are missing not at random
(MNAR) if the probability of being missing depends on
unobserved values including possibly the missing value itself.
Small amounts of missing data can be imputed using simple
methods, but when multiple variables have missing values,
multiple imputation is the most common approach
[130,195,196]. Most imputation methods assume data are
MAR, but this cannot be proved, and these methods require
assuming models for the relationship between missing values
and the other observed variables. Use of a separate category
indicating missing data has been shown to bias results [195].
The plausibility of assumptions made in missing data
analyses is generally unverifiable. When more than
minimal amounts of data are imputed it is valuable to
present results obtained with imputation alongside those
from complete case analyses, and to discuss important
differences (Item 18).
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patient. RFS was defined as time from mastectomy to the first
occurrence of either locoregional or distant recurrence, contralat-
eral tumour, secondary tumour or death; overall survival as time
from operation to death.’ [66]
Explanation
Survival analysis is based on the elapsed time from a relevant
time origin, often the date of diagnosis, surgery, or randomization,
to a clinical endpoint. That time origin should always be specified.
Most prognostic studies in cancer examine few endpoints,
mainly death, recurrence of disease, or both, but these endpoints
are often not clearly defined (see Box 3). Analyses of time to death
may be based on either deaths from any cause or only cancer
related deaths. The endpoint should be defined precisely and not
referred to just as ‘survival’ or ‘overall survival’. If deaths from
cancer are analyzed, it is important to indicate how the cause of
death was classified. If known, it can also be helpful to indicate
what records (such as death certificate or tumor registry) were
examined to determine the cause of death.
If there was a specific rationale for choosing the primary clinical
endpoint, it should be stated. For example, if the studied marker is
believed to be associated with the ability of a cell to metastasize, an
endpoint that focuses on distant recurrences might be justified. For
a marker believed to be associated with sensitivity to radiation
therapy, local-regional recurrences in a population of patients who
received radiotherapy following primary surgery might be
relevant.
The lack of standardized definitions also affects the analysis of
recurrence of disease. Relapse-free survival, disease-free survival
(DFS), remission duration, and progression-free survival are the
terms most commonly used; however, they are rarely defined
precisely. The first three imply that only patients who were
disease-free after initial intervention were analyzed (although this
is not always the case), while for progression-free survival all
patients are generally included in the analysis. If authors analyze
disease recurrence they should precisely define that endpoint, in
particular with respect to how deaths are treated. Similarly,
outcomes such as distant DFS should be defined precisely.
Further, standardized definitions across studies would be desirable
[67].
Some endpoints require subjective determination (for example,
progression-free survival determined by a review of radiographic
images). For this reason, it can also be helpful to report, if known,
whether the endpoint assessments were made blinded to the
marker measurements. It is helpful to report any additional steps
taken to confirm the endpoint assessments (for example, a central
review of images for progression determination).
The time origin was not stated for at least one endpoint in 48%
of 132 papers in cancer journals reporting survival analyses [64].
At least one endpoint was not clearly defined in 62% of papers.
Among the 106 papers with death as an endpoint, only 50 (47%)
explicitly described the endpoint as either any death or only cancer
death. In 64 papers that reported time to disease progression, the
treatment of deaths was unclear in 39 (61%). Outcomes were
precisely defined in 254 of 331 studies (77%) included in 20
published meta-analyses [18]. The authors noted, however, that
‘this percentage may be spuriously high because we considered all
mortality definitions to be appropriate regardless of whether any
level of detail was provided’.
Item 8. List all candidate variables initially examined
or considered for inclusion in models.
Example
‘Cox survival analyses were performed to examine prognostic
effects of vitamin D univariately (our primary analysis) and after
adjustment for each of the following in turn: age (in years), tumor
stage (T2, T3, or TX v T1), nodal stage (positive v negative),
estrogen receptor status (positive or equivocal v negative), grade (3
Box 3. Clinical Outcomes
It is important to clearly define any endpoints examined (see
Item 7). Events typically considered in tumor marker
prognostic studies include death due to any cause, death
from cancer, distant recurrence, local recurrence, tumor
progression, new primary tumor, or tumor response to
treatment. The clinical endpoint is reached when the event
occurs. For death, recurrence, progression, and new primary
tumor, there is usually interest not only in whether the event
occurs (endpoint reached), but also the time elapsed (for
example, from the date of surgery or date of randomization
in a clinical trial) until it occurs. Time until last evaluation is
used for patients without an event (time censored). The
clinical outcome is the combination of the attainment or
non-attainment of the endpoint and the time elapsed. Such
clinical outcomes are referred to as time-to-event outcomes.
Commonly examined outcomes in tumor marker prognostic
studies are disease-free survival (DFS), distant DFS, and
overall survival (OS). Different event types are sometimes
combined to define a composite endpoint, for example DFS
usually includes any recurrence (local, regional, or distant)
and death due to any cause. For composite endpoints, the
time-to-event is the time elapsed until the first of any of the
events comprising the composite endpoint occurs. As
recently shown, a majority of articles failed to provide a
complete specification of events included in endpoints [197].
Many clinical endpoints do not have standard definitions,
although there have been some recent efforts to
standardize definitions for some disease sites. The STan-
dardized definitions for Efficacy End Points (STEEP) system
[67] proposed standardized endpoint definitions for
adjuvant breast cancer trials to address inconsistencies
such as the fact that new primary tumors, non-cancer
death, and in situ cancers may or may not be included as
events in DFS for breast cancer. Different names may be
used interchangeably for one survival time outcome, for
example, recurrence-free survival and DFS. Furthermore,
there is not always agreement on which endpoint is the
most relevant endpoint to consider in a particular disease
setting. For example, reliable information about cause of
death is sometimes not available, so considering death
due to any cause is often preferred. In some situations, for
example, in an older patient population with small risk of
dying from the cancer, it can be argued that death due to
cancer is more relevant because it is expected that many
deaths will be unrelated to the cancer and including them
in the endpoint could make the estimated prognostic
effect of the marker difficult to interpret.
The endpoints to be examined should be decided on the
basis of clinical relevance. The results for all endpoints that
were examined should be reported regardless of the
statistical significance of the findings (see Items 15 to 17
and Box5). A demonstratedassociation ofamarker withone
of these endpoints does not guarantee its association with
all oftheendpoints.Forexample, local recurrence may bean
indicationofinsensitivitytolocalorregionaltherapy(suchas
radiation therapy) whereas distant recurrence requires that
tumor cells have the ability to metastasize. Different markers
may be indicative of these distinct characteristics.
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adjuvant hormone therapy (any v none), body mass index (BMI; in
kilograms per square meter), insulin (in picomoles per liter), and
season of blood draw (summer v winter). Simultaneous adjustment
for age, tumor stage, nodal stage, estrogen receptor status, and
grade was then performed.’ [68]
Explanation
It is important for readers to know which marker measurements
or other clinical or pathological variables were initially considered
for inclusion in models, including variables not ultimately used.
The reasons for lack of inclusion of variables should be addressed;
for example, variables with large amounts of missing data (see Box
2). Authors should fully define all variables and, when relevant,
they should explain how they were measured.
All of the variables considered for standard survival analyses
should be measured at or before the study time origin (for
example, the date of diagnosis) [69,70]. (For tumor markers, this
means the measurements are made on specimens collected at or
before study time origin even if the actual marker assays are
performed at a later time on stored specimens.) Variables
measured after the time origin, such as experiencing an adverse
event, should more properly be considered as outcomes, not
predictors [71]. Another example is tumor shrinkage when the
time origin is diagnosis or start of treatment. Statistical methods
exist to allow inclusion of variables measured at times after the
start of follow-up (‘time-dependent covariates’) [72], but they are
rarely used and require strong assumptions [73,74].
A list of the considered candidate variables was presented in
71% of a collection of 331 prognostic studies [18]. Of 132 articles
published in cancer journals, 18 (13%) analyzed variables that
were not measurable at the study time origin [64], of which 15
compared the survival of patients who responded to treatment to
survival of those who did not respond. Out of 682 observational
studies in clinical journals that used a survival analysis, 127 (19%)
included covariates not measurable at baseline [69].
Item 9. Give rationale for sample size; if the study
was designed to detect a specified effect size, give the
target power and effect size.
Examples
‘Cost and practical issues restricted the sample size in our study
to 400 patients. Only 30 centres entered ten or more patients in
AXIS, so for practical reasons, retrieval of samples began with
these centres within the UK, continuing until the target sample
size of 400 had been reached.’ [75]
‘Assuming a control survival rate of 60% and 50% of patients
with high TS expression or p53 overexpression, then analysis of
tissue samples from 750 patients will have 80% power to detect an
absolute difference of 10% in OS associated with the expression of
either of these markers.’ [76]
‘Althoughitwasalargetrial,FOCUSstilllackedpowertobesplit
into test and validation data sets. It was therefore treated as a single
test-set, and positive findings from this analysis need to be validated
in an independent patient population. A 1% significance level was
used toallow formultipletesting.Thenumber ofassessablepatients,
variant allele frequencies, and consequent power varied by
polymorphism; however, with an overall primary outcome event
rate of 20%, we could detect differences of 10% (eg, 14% v 24%)
between any two treatment comparisons, and we could detect a
linear trend in genotype subgroups varying by 6% (eg, 13% v 19% v
25%) with a significance level of 1% and 90% power … Even with a
dropout rate of 14% for incomplete clinical data, there was 85%
power at a significance level of 1% to detect a 10% difference from
14% to 24% in toxicity for any two treatment comparisons or a
linear trend in genotype subgroups from 13% to 19% to 25%.’ [77]
Explanation
Sample size has generally received little attention in prognostic
studies, perhaps because these studies are often performed using
pre-existing specimen collections or data sets. For several reasons,
the basis for a sample size calculation in these studies is less clear
than for a randomized trial. For example, the minimum effect size
of interest for a prognostic marker study may be quite different
from that of an intervention study, and the effect of the marker
adjusted for other standard variables in a multivariable model may
be of greater interest than the unadjusted effect. Authors should
explain the considerations that led to the sample size. Sometimes a
formal statistical calculation will have been performed, for
example calculation of the number of cases required to obtain
an estimated hazard ratio with prescribed precision or to have
adequate power to detect an effect of a given size. More often
sample size will be determined by practical considerations, such as
the availability of tumor samples or cost. Even in this situation, it is
still helpful to report what effect size will be detectable with
sufficient power given the pre-determined sample size.
Several authors have addressed the issue of sample size
calculations applicable to prognostic studies [78–80]. The most
important factor influencing power and sample size requirement
for a study with a time-to-event outcome is the number of
observed events (effective sample size), not the number of patients.
For a binary outcome, the effective sample size is the smaller of the
two frequencies, ‘event’ or ‘non-event’. Additional factors, such as
the minimum detectable effect size, distribution of the marker (or
the prevalence of a binary marker), coding of the marker (whether
treated as a continuous variable or dichotomous; see Item 11 and
Box 4), and type of analysis method or statistical test also have an
impact. As a consequence of the importance of the number of
events, studies of patients with a relatively good prognosis, such as
lymph node negative breast cancer, require many more patients or
longer follow-up than studies of metastatic disease in which events
are more frequently observed. Choice of an endpoint that includes
recurrence as an event in addition to death will also result in more
observed events and higher power, an important reason as to why
DFS is often preferred as an endpoint [81].
Sample size requirements will differ depending on the goal of
the study and stage of development of the marker. For markers
early in the development process, investigators may be most
interested in detecting large effects unadjusted for other variables
and may be willing to accept higher chances of false positive
findings (that is, a higher type I error) to avoid missing interesting
marker effects. Targeting larger effect sizes and allowing higher
error rates will result in a smaller required sample size. As a
prognostic marker advances in the development process, it will
typically be studied in the context of regression models containing
other clinically relevant variables, as discussed in Item 10d. These
situations will require larger sample sizes to account for the
diminished size of marker effects adjusted for other (potentially
correlated) variables and to offer some stability even when multiple
variables will be examined and model selection methods will be
used.
When the goal is to identify the most relevant variables in a
model, various authors have suggested that at least 10 to 25 events
are required for each of the potential prognostic variables to be
investigated [82–85]. Sometimes the primary focus is estimation of
the marker effect after adjustment for a set of standard variables,
so correctly identifying which of the other variables are really
important contributors to the model is of less concern. In this
situation, sample size need not be as large as the 10 to 25 events
per variable rule would recommend [86] and other sample size
calculation methods that appropriately account for correlation of
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Required sample sizes are substantially larger if interactions are
investigated. For example, an interaction between a marker and a
treatment indicator may be examined to assess whether a marker
is predictive for treatment benefit (see Box 3).
Several studies have noted the generally small sample size of
published studies of prognostic markers. In a review of lung cancer
prognostic marker studies, the median number of patients per
study was 120 [88], while three quarters of studies in a review of
osteosarcoma prognostic marker literature included fewer than
100 patients [89]. In a systematic review of tumor markers for
neuroblastoma, 122 (38%) of 318 eligible reports were excluded
because the sample size was 25 or lower [90]. As mentioned above,
the number of events is a more relevant determinant of power of a
study, and it is usually much smaller and often not even reported
(see Item 12).
Twenty meta-analyses that included 331 cancer prognostic
studies published between 1987 and 2005 were assessed to
determine the quality of reporting for the included studies [18].
Only three (0.9%) of the 331 studies reported that a power
calculation had been performed to determine sample size.
Statistical Analysis Methods
Item 10. Specify all statistical methods, including
details of any variable selection procedures and other
model-building issues, how model assumptions were
verified, and how missing data were handled.
After some broad introductory observations about statistical
analyses, we consider this key item under eight subheadings.
All the statistical methods used in the analysis should be
reported. A sound general principle is to ‘describe statistical
methods with enough detail to enable a knowledgeable reader with
access to the original data to verify the reported results’ [91]. It is
additionally valuable if the reader can also understand the reasons
for the approaches taken.
Moreover, for prognostic marker studies there are many
possible analysis strategies and choices are made at each step of
the analysis. If many different analyses are performed, and only
those with the best results are reported, this can lead to very
misleading inferences. Therefore, it is essential also to give a
broad, comprehensive view of the range of analyses that have been
undertaken in the study (see also the REMARK profile in Item
12). Details can be given in supplementary material if necessary
due to publication length limitations.
Analysis of a marker’s prognostic value is usually more complex
than the analysis of a randomized trial, for which statistical
principles and methods are well developed and primary analysis
plans are generally pre-specified. Many of the marker analysis
decisions can sensibly be made only after some preliminary
examination of the data and therefore generally only some key
Box 4. Continuous Variables
Many markers are recorded as continuous measurements, but
in oncology it is common to convert them into categorical
form by using one or more cutpoints (Item 11). Common
reasons are to simplify the analysis, to make it easier for
clinicians to use marker information in decision making,
because the functional form of the influence of a marker is
often unknown, and to facilitate graphical presentation (for
example, Kaplan-Meier curves). Although categorization is
required for issues such as decision making, it has to be
stressed that categorization of continuous data is unnecessary
for statistical analysis. The perceived advantages of a simpler
analysis come at a high cost, as explained below. The same
considerations apply to both the marker being studied and
other continuous variables.
Categorization
Categorization allows researchers to avoid strong assump-
tions about the relationship between the marker and risk.
However, this comes at the expense of throwing away
information. The information loss is greatest when the
marker is dichotomized (two categories).
It is well known thatthe results of analyses can vary if different
cutpoints are used for splitting. Dichotomizing does not
introduce bias if the split is at the median or some other pre-
specified percentile, as is often done. If, however, the cutpoint
is chosen based on multiple analyses of the data, in particular
taking the value which produced the smallest P value, then
the P value will be much too small and there is a large risk of a
false positive finding [198]. An analysis based on the so-called
optimal cutpoint will also heavily overestimate the prognostic
effect, although bias correction methods are available [199].
Even with a pre-specified cutpoint, dichotomization is
statistically inefficient and is thus strongly discouraged
[153,200,201]. Further, prognosis is usually estimated from
multivariable models so if cutpoints are needed as an aid in
classifying people into distinct risk groups this is best done
after modeling [153,202].
Categorizing a continuous variable into three or more
groups reduces the loss of information but is rarely done
in clinical studies (by contrast to epidemiology). Even so,
cutpoints result in a model with step functions which is
inadequate to describe a smooth relationship [110].
Keeping variables continuous
A linear functional relationship is the most popular approach
for keeping the continuous nature of the covariate. Often that
is an acceptable assumption, but it may be incorrect, leading
to a mis-specified final model in which a relevant variable may
not be included or in which the assumed functional form
differs substantially from the unknown true form.
A check for linearity can be done by investigating possible
improvement of fit by allowing some form of nonlinearity.
For a long time, quadratic or cubic polynomials were used to
model non-linear relationships, but the more general family
of fractional polynomial (FP) functions provide a rich class of
simple functions which often provide an improved fit [203].
Determination of FP specification and model selection can
be done simultaneously with a simple and understandable
presentation of results [108,110].
Spline functions are another approach to investigate the
functional relationship of a continuous marker [101]. They are
extremely flexible, but no procedure for simultaneously
selecting variables and functional forms has found wide
acceptance. Furthermore, even for a univariable spline model,
reporting is usually restricted to the plot of the function because
presentation of the parameter estimates is too complicated.
When the full information from continuous variables is used
in the analysis, the results can be presented in categories to
allow them to be used for tasks such as decision making.
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will be required, including coding of variables, handling of missing
data, and specification of models. It would be useful to clarify
which of these decisions were pre-specified and which were made
post hoc or even in deviation from the original analysis plan.
Reporting of key features of an analysis is important to allow
readers to understand the reasons for the specific approach chosen
and to assess the results. No study seems yet to have investigated in
detail the large variety of statistical methods used and the quality
of their reporting, but the common weaknesses in applying
methods and the general insufficient reporting of statistical aspects
of a multivariable analysis have been well known for many years.
Empirical investigations of published research articles seem to
concentrate more on randomized trials and epidemiological
studies, but the methods and problems of multivariable models
in the latter are similar to prognostic studies. Concato et al.
identified 44 articles which considered risk factors in the
framework of a logistic regression model or a proportional hazard
model [92]. All had at least one severe weakness, and they
concluded ‘the findings suggest a need for improvement in the
reporting and perhaps conducting of multivariable analyses in
medical research’. Recently Mallett and colleagues assessed 50
articles reporting tumor marker prognostic studies for their
adherence to some items from the REMARK checklist [20]. In
49 out of 50 studies (98%), the Cox model was used. Proportional
hazards is one of the key assumptions of this model but only four
articles (8%) reported testing this assumption (see Item 18).
Sigounas et al. assessed 184 studies on prognostic markers for acute
pancreatitis. Multivariable analyses were performed in only 15 of
them, of which only one provided all details requested in Item 10
[21]. Although bad reporting does not mean that bad methods
were used, the many studies identifying specific issues of bad
reporting clearly show that a substantial improvement of reporting
of statistical methods is needed [18,21,33,64,93–98].
In the following sections we consider specific aspects of analyses
under eight headings. Not all aspects will be relevant for some
studies. More extensive discussions of statistical analysis methods
for binary outcome and for survival data can be found elsewhere
[73,99–111].
a. Preliminary data preparation
Example
‘Ki67 was measured as a continuous score which is typically
positively skewed. Analysis was undertaken by log transforming
Ki67 and using log(Ki67) as a covariate to investigate whether
there is a linear increase in the probability of relapse with
increasing Ki67 value.’ [112]
Explanation
Some assessment of the data quality usually takes place prior to
the main statistical analyses of the data, and some data values may
be changed or removed if they are deemed unreliable. These
manipulations and pre-modeling decisions could have a substantial
impact on the results and should be reported, but rarely are [113–
117].
There are many examples of steps typically taken in initial data
analyses. The distribution of the marker values and distributions of
any other variables that will be considered in models should be
examined for evidence of extreme values or severe skewness. It may
be appropriate to truncate or omit extreme outliers. Preliminary
transformations of specific variables (for example, logarithm or
square root) may be applied to remove severe skewness. For
categorical variables, re-categorization is often performed to
eliminate sparse categories (for example, histological types of
tumors). Graphical representations or summary statistics calculated
to assess the distribution of the marker or other variables (for
example, boxplot; mean, median, SD, range, and frequencies)
should bedescribedbecause different methodswill depictfeaturesof
the data with varying degrees of sensitivity (such as outliers and
skewness). If some marker measurements were judged to be
unreliable and consequently omitted or adjusted to lessen their
influenceintheanalysis,itis recommended thesedetails be reported
as they can be informative about the robustness of the assay and
stability of the analysis results. It is helpful to report these early steps
of the analysis along with the number of data values that were
excluded or somehow modified (see also Items 12 and 13).
b. Association of marker values with other variables
Example
‘The associations of cathepsin-D with other variables were
tested with non-parametric tests: with Spearman rank correlation
(rs) for continuous variables (age, ER, PgR), and the Wilcoxon
rank-sum test or Kruskal-Wallis test, including a Wilcoxon-type
test for trend across ordered groups where appropriate, for
categorical variables.’ [29]
Explanation
Early steps in an analysis may include an examination of the
relationship of the marker to other variables being considered in
the study. These variables might include established clinical,
pathologic, and demographic covariates (see Items 13 and 14). If
more than one marker is being evaluated in a study, the
relationships between the multiple markers should be examined.
Methods for summarizing associations with other variables (for
example, correlation coefficients, chi-square tests, and t-tests)
should be described. Extreme or unusual associations may be
relevant to the validity of analyses and stability of results and may
suggest further data modifications are advisable (see section a
above) or that certain variables are redundant.
c. Methods to evaluate a marker’s univariable associ-
ation with clinical outcome
Example
‘Median survival time and median DFI [disease free interval]
for the whole test set were estimated using the Kaplan-Meier
product limit method. Univariate associations between survival
time, DFI, and glucose were examined using Cox proportional
hazards regression models. These analyses examined glucose as a
continuous variable, using an increment of 70 mg/dL to derive
hazard ratios, and adjusted for time of blood draw to control for
circadian effects on glucose levels … Wald Chi-square P values
were used to calculate univariate statistical significance, and 95%
confidence intervals were estimated.’ [118]
Explanation
A marker’s association with clinical outcome is of key importance.
The first evaluation will usually be conducted without adjustmentfor
additional variables, that is, a univariable analysis. The method of
analysis(forexample,logranktestorestimatedeffect with confidence
interval in a Cox regression or a parametric model for survival data),
including options such as choice of test statistic (for example, Wald
test, likelihood ratio test, or score test), should be reported.
Any variable codings or groupings, or transformations of
continuous values applied to the marker variable or any other
variables, should be stated to allow for proper interpretation of the
estimated associations (see Box 4 and Item 11).
In addition, similar analyses may be conducted to examine the
association of other variables with clinical outcome.
d. Multivariable analyses
Examples
‘A Cox regression model was used with individual marker as the
exposure variables and OS [overall survival] (from time of surgery
to time of death or end of current follow-up) as the outcome. The
analyses were adjusted simultaneously for sex, age, tumour size,
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of post-operative adjuvant therapies.’ [76]
‘Univariable and multivariable Cox regression models ad-
dressed CSM after NU or SU. Covariates consisted of patholog-
ically determined T stage (pT1 versus pT2 versus pT3 versus pT4),
N stage (N0 versus N1–3), tumour grade (I versus II versus III
versus IV), primary tumour location (ureter versus renal pelvis),
type of surgery (NU with bladder cuff versus NU without bladder
cuff versus SU), year of surgery, gender (male versus female) and
age. Since pT and pN stages, as well as tumour grade, may
contribute to a multiplicative increase in CSM rate, we tested
three first-degree interactions between these variables. Specifically,
multivariable interaction tests were performed between pT and
pN stages, between T stage and tumour grade and between N
stage and tumour grade.’ [119]
‘For both models 1 and 2 a competing risk analysis was
performed using cause-specific hazards. This analysis follows
separate Cox models for each event assuming proportional
hazards. In such competing risks analyses with two endpoints, it
is possible to interpret both cause-specific hazard ratios simulta-
neously for each risk factor. Cumulative incidence functions have
been displayed for each endpoint. The proportional hazard
assumptions were assessed by study of the graphs of the
Schoenfeld’s residuals; this technique is especially suitable for
time-dependent covariates.’ [120]
Explanation
Univariable analyses are useful but, except in early studies, are
generally insufficient because of the possible relationship of the
marker with other variables. Thus the prognostic value of the marker
after adjustment for established prognostic factors, as estimated from
a multivariable model (see Item 17), will be of major interest. To
facilitate comparison of the unadjusted and adjusted measures of
association,itishelpfultoreportresultsfromunivariableanalysesthat
used the same general approach as the approach used for the
multivariable analysis. For example, if multivariable analyses
adjusting for standard prognostic factors are based on a Cox
regression model with the log-transformed marker value as one of the
independent variables, then it is helpful also to report the
corresponding results of a univariable Cox regression analysis. This
allows for direct assessment of how the marker’s regression coefficient
is altered by inclusion of standard covariates in the model.
Whereas the Cox proportional hazards model allows a flexible
form of baseline hazard, parametric models assume specific
functional forms [109,121,122]. Parametric models [123] will be
statistically more efficient if the model is correct and may be more
easily adaptable to situations involving complex censoring
patterns, but if the assumed functional form of the baseline
hazard is incorrect, they can be misleading. It is important that
authors report which model was used.
Multivariable methods can also be used to build prognostic
models involving combinations of several candidate markers or
even many hundreds of markers (for example, gene expression
microarray data). Although the same basic analysis principles
apply to these situations, even greater care must be taken to ensure
proper fit of such models and avoid overfitting, and to rigorously
evaluate the model’s prognostic performance. These topics are
covered in many articles and books [99,101,108,110,124–126]
and are not a focus of this paper.
Investigators may use statistical approaches other than classic
multivariable regression to take into account multiple variables.
Such techniques include classification and regression trees and
artificial neural networks. Their detailed discussion is beyond the
scope of the current guidelines; for details the reader is referred
elsewhere [107].
e. Missing data
Example
‘Thirteen patients (all either ductal carcinoma, lobular carcino-
ma or mixed histology) had no grade information recorded in the
data and one patient had no tumour size recorded. These patients
were included in the analysis using multiple imputation methods to
estimate the missing values. The hazard ratios were derived from
the average effect across 10 augmented datasets, with the
confidence intervals and significance tests taking into account
the uncertainty of the imputations. The multiple imputation was
performed by the MICE library within the S-Plus 2000 Guide to
Statistics Volumes 1 and 2 (MathSoft, Seattle, WA, USA) … ’
[127]
Explanation
Almost all prognostic studies have missing marker or covariate
data for some patients because clinical databases are often
incomplete. Also, some marker assays may not yield interpretable
results for all specimens. However, not all papers report in detail
the amount of missing data and very few attempt to address the
problem statistically [33].
Authors should report the number of missing values for each
variable of interest. They should give reasons for missing values if
possible, and indicate how many individuals were excluded
because of missing data when describing the flow of participants
through the study (see Item 12). Many authors omit cases without
all relevant information from all analyses or they may vary who is
included according to which variables are included in the analysis.
Including only cases with complete data may greatly reduce the
sample size and potentially lead to biased results if the likelihood of
being missing is related to the true value (see Box 2) [33,128–131].
Modern statistical methods exist to allow estimation (imputation)
of missing observations. These issues are clarified in Box 2.
Authors should describe the nature of any such analysis (for
example, multiple imputation) and specify assumptions that were
made (for example, ‘missing at random’).
In a review of 100 prognostic articles, the percentage of eligible
cases with complete data was obtainable in only 39; in 17 of these
articles more than 10% of patients had some missing data. The
methods used to handle incomplete covariates were reported in
only 32 out of 81 articles with known missing data [33].
f. Variable selection
Example
‘When using a stepwise variable selection procedure to identify
independent factors prognostic for survival, variables were added
using forward selection according to a selection entry criterion of
0.05 and removed using backward elimination according to a
selection stay criterion of 0.05. The importance of a prognostic
factor was assessed via Wald-type test statistics, the hazard ratio
and its 95% confidence interval for survival.’ [132]
Explanation
Sometimes several multivariable models containing different
subsets of variables are considered. The rationale for these choices
and details of any model selection strategies used should be
described. The REMARK profile can provide a concise summary
of all analyses performed (Item 12).
If patients in the study received different treatments, one or
more variables indicating treatments received can be considered in
models, treatment can be used as a stratification factor, or separate
models may be built for each treatment. For many cancer types,
there are a few generally accepted staging variables or other
clinical or pathologic variables that would be available in most
cases, and these variables would usually be considered in
multivariable models (see also Item 17).
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which helps to avoid biases caused by data-dependent model
selection. More often, however, many candidate variables are
available and some type of variable selection procedure is sensible
in order to derive simpler models which are easier to interpret and
may be more generally useful [108,133]. It is particularly
important to state if the variables included in a reported model
were determined using variable selection procedures. Any
selection procedures used should be described (for example,
stepwise regression or backward elimination) along with specific
criteria used to determine inclusion or exclusion of variables from
the model (for example, P values) or to select a best fitting model
(for example, Akaike information criterion) [101]. It is well known
that, unless sample sizes are large, use of variable selection
procedures will lead to biased parameter estimates and exagger-
ated measures of statistical significance [66,121,134]. For this
reason, Item 17 requests that results from a particular multivar-
iable model which includes the marker along with ‘standard’
prognostic variables, regardless of statistical significance, be
reported.
g. Checking model assumptions
Examples
‘In the basic form of the Cox regression model, the coefficients
corresponded to the logarithm of the HR and were constant in
time. This assumption was graphically evaluated by means of
smoothed Schoenfeld residuals and tested as suggested by
Grambsch and Therneau.’ [135]
‘The proportional hazards assumptions were checked by plots of
log(- log survival time) versus log time.’ [136]
‘We evaluated the proportional hazards assumption by adding
interaction terms between the time-dependent logarithm of follow-
up time plus 1 and tamoxifen treatment, ERaS118-P status, or
both and found no evidence for nonproportional hazards
(P=.816, .490, and .403, respectively).’ [24]
Explanation
Any statistical model, univariable or multivariable, makes
certain assumptions about the distributions of variables or the
functional relationships between variables. For example, the Cox
proportional hazards regression model commonly used for survival
data requires several important assumptions, including propor-
tional hazards and linear relationships between continuous
covariates and the log hazard function. Proportional hazards
assumptions are often violated when there is long follow-up, for
example, for certain types of cancers in which a portion of patients
can be considered cured. How the variables are coded or
transformed will also affect the appropriateness of linear versus
non-linear relationships (see Item 11 and Box 4).
Methods used to empirically check model assumptions should
be reported. For example, residual plots and models containing
time-by-covariate interactions are often used to diagnose depar-
tures from linearity and proportional hazards [122,137–139].
Influential points and outliers can often be detected by diagnostic
plots such as added variable plots [140]. Parametric survival
models, such as lognormal or Weibull models, make additional
assumptions about the distribution of the survival times [123]. The
suitability of parametric models can be checked using methods
such as residual plots and goodness of fit tests [109,121]. Many
extensions of the Cox model have been proposed to handle
departures from the basic assumptions [138,139] but they will not
be discussed here. More complex models require larger sample
sizes than often are available in tumor marker prognostic studies to
avoid overfitting to noise in the data [107,141].
Alternative models evaluated for purposes of sensitivity analyses
should also be described (see Item 18).
h. Model validation
Examples
‘For internal validation of the multivariate models, 1000
bootstrap samples were created and stepwise Cox regression
analysis was applied to each sample. The relative frequencies of
inclusions of the respective factors were calculated.’ [142]
‘For this study, and future studies using this TMA, the primary
investigator is given access to all clinical, outcome, and TMA data
from the training set only. The training set is used to generate and
refine hypotheses regarding the biomarker under study. Significant
findings are then formally presented … Those findings considered
to be of clinical and scientific interest are then re-tested on the
validation set. A separate researcher who did not participate in the
training set analysis performs the re-testing on the validation set.
Our statistical approach is intended to minimize false positive
results, particularly with subgroup analysis.’ [143]
Explanation
Invariably, the strongest evidence for the validity of results is
confirmation of the findings on data not involved in the original
analysis [144,145]. The ideal approach is to confirm findings from
the main (final) model on completely independent data, preferably
collected by different investigators but under pre-defined appro-
priate conditions. If successful, this approach would indicate that
the results are transportable to other settings. This would be a type
of ‘external validation’. A prospectively designed and conducted
clinical trial is the strongest form of validation, but trials designed
with the primary objective to validate a prognostic marker or
model are rare. More often, evaluations of markers occurring
within trials are secondary aims in trials primarily designed to
evaluate a treatment or other intervention. The marker evaluation
could occur during the trial, or the evaluation might take place
even years after completion of the trial using specimens banked
during the course of the trial. This latter option has been referred
to as a ‘prospective-retrospective’ design, and it can provide a high
level of evidence for the utility of a marker if conducted under
appropriate conditions [146]. Complete specification of the
marker assay method and model (if relevant), a pre-specified
analysis plan, and enforcement and documentation of lock-down
of marker analytical results prior to unblinding of clinical outcome
data (see also Item 5) are among the conditions that should be
satisfied for a rigorous prospective-retrospective validation.
A completely independent data set (a ‘similar’ study) often will
not be available, but ‘internal’ validation procedures, such as
cross-validation, bootstrapping, or other data resampling methods
[133,147], are useful to give insights into critical issues such as bias
of regression parameter estimates, overoptimism of prognostic
model discriminatory ability, or stability of the model derived (see
also Item 18). Internal validation involves holding out some
portion of the data (‘test set’) while a model is built on the
remaining portion (‘training set’); when the model is completely
specified on the training set, it is then evaluated (tested) on the
held-out data. A limitation of internal validation is that there may
be biases affecting the entire data set that will not be detected by
internal validation because the biases will affect the training and
test sets equally [46]; however, if a model has been seriously
overfitted to random noise in the training set, properly performed
internal validation should reveal failure of the model on the test
data. The study report should include a description of any
validations that were performed, internal or external.
For internal validation, the specific validation algorithm used
should be described (for example, bootstrapping, 10-fold or leave-
one-out cross-validation) [147–149]. If a study performs any
external validation, basic details of the study population, design,
and analysis approach should be provided. It should be clarified
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different centers or periods as the samples used to develop the
model. In cases where the whole study represents a validation of a
previously developed model this should be stated, along with
proper reference to the previous study that developed that model.
Item 11. Clarify how marker values were handled in
the analyses; if relevant, describe methods used for
cutpoint determination.
Examples
‘In the regression models, steroid receptors content and age
were considered as continuous variables, the latter in its original
measure scale and the former in terms of its natural logarithms
because of the positive skew of its distribution. Null values for
steroid receptor content were arbitrarily set to 1 considering a
sensitivity threshold value of 2 fmol/mg of cytosolic protein.’ [135]
‘Hazard ratios (HRs) and 95% CIs for CRP and SAA tertiles
were estimated using Cox proportional hazards regression … CRP
and SAA values were log transformed to account for skewness, and
HRs and 95% CIs were generated for these continuous measures.’
[150]
‘As there was no clinically defined cutoff point for serum IL-6
level, the median was used to divide the patients into two groups
(low versus high serum IL-6 level).’ [151]
‘In the absence of a reliable gold standard and following
distributional studies, we used the 25th percentile of observed
hormonal receptor mRNA expression levels and the median of
observed MAP-Tau mRNA levels as thresholds for categorization
of tumors to positive or negative cases.’ [152]
Explanation
Many markers are measured as continuous variables. A central
question is how to analyze these variables, including how to
incorporate them in a multivariable model. The same consider-
ations apply to several standard variables, such as age and tumor
size.
Two main approaches are to keep the variables as continuous
(but not necessarily assume a linear relation with the outcome), or
to group the data into categories. Although categorization is
ubiquitous in cancer studies, there are some major concerns about
that approach, as discussed in Box 4 [153]. The common practice
of using only two categories makes it impossible to detect any
nonlinearity in the relation between the variable and outcome.
However, for later clinical use, dichotomization may be necessary.
Authors should report how each continuous variable was
incorporated into the analyses. For categorized variables, they
should specify the cutpoints and how they were chosen. It is
especially important to declare any cutpoints chosen after
examining many options (see Box 4). For continuous variables,
authors should clarify whether the data were kept on the original
scale or, say, log transformed, and indicate whether the
relationship was modeled as linear or non-linear, and how. If
treated as linear, it is helpful to report whether the assumption of a
linear relationship for continuous variables was checked (Box 4).
Similar concerns relate to variables with three or more ordered
categories, such as Karnofsky score. For markers and other
variables with several categories (for example, from three to six) it
is important to specify how they were treated in the analyses. If
dummy variables were created, it is important to specify how they
were defined and analyzed [110]. If multiple methods of coding
dummy variables are considered in the analysis, there is a risk of
selective reporting of the results that look most interesting.
Reviews of published prognostic factor studies show that
categorization is very common, with almost all studies reporting
results for dichotomized marker values [15]. Further, there is
usually considerable variation in cut-off values across studies,
hindering a sound comparison of results. For example, a review of
p53 in bladder cancer found that definitions of positive p53
staining cut-off values ranged from 1% to 75% [154].
Results
Data
Item 12. Describe the flow of patients through the
study, including the number of patients included in each
stage of the analysis (a diagram may be helpful) and
reasons for dropout. Specifically, both overall and for
each subgroup extensively examined report the number
of patients and the number of events.
Examples
‘Tumor samples from 375 patients were sent to the central
laboratory for EGFR assays by IHC, and evaluable assay results
were obtained for 325 patients (87%). Among the 50 patients with
unevaluable results, 38 (76%) had insufficient tumor cells in their
tumor sample, six (12%) had extensive necrosis, three (6%) had
inadequate control staining, two (4%) had poor tumor preserva-
tion, and one (2%) had a broken slide.’ [155]
See also Figure 1.
Explanation
The interpretation of prognostic studies depends on having a
good understanding of the patients included in the study, the
methods used, the analyses conducted, and the amount of data
available at each stage. In contrast to RCTs, exploratory analyses
play a much more important role (see Item 10). In general, several
analyses are conducted of which only some are fully reported, with
the results of others mentioned only briefly in the text (and easily
overlooked) or not reported at all. This selective reporting practice
gives rise to biased results and biased interpretation and should be
avoided. Important information, such as the effective sample size
(see Item 9), is usually not given for many analyses. At present,
hardly any report fully meets the needs of readers [20,21].
One way to ensure completeness of reporting of key information
is via a structured display. Even for RCTs, which are relatively
straightforward, it is often impossible to understand from the text
why the numbers of patients in analyses differs from the numbers
enrolled in the trial. Thus the CONSORT flow diagram [8] has
become a widely used simple depiction of the flow of participants
in an RCT from enrolment through to inclusion in the final
analysis.
Analyzing and reporting prognostic studies is in general more
complicated than for RCTs. Therefore, we suggest two comple-
mentary displays that authors can use to summarize key aspects of
a prognostic study, especially the derivation of the sample and
details of the analyses performed. A flow diagram provides an easy
to follow view of the major changes in the population as the study
proceeds; a study profile (see below) provides a succinct summary
of the analyses performed and the data used in them.
The upper part of a study profile can be used to show the
derivation of the sample of patients included in the study. It is
analogous to the CONSORT [8] and STROBE [156] flow
diagrams, but gives the information in a more condensed way and
may make a flow diagram, as shown in the examples, redundant
(see also Item 2). Its inclusion in reports of prognostic studies
would help to clarify the extent to which the analyzed patients
were selected from a larger series.
Knowing how many patients were included in a study is
important, but information should be given about the amount of
data available for each analysis. Missing values (see Box 2) are
much more common in retrospective studies than in prospective
studies due to the use of historical data. The complete case analysis
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the number of patients and events will often vary across analyses
according to the choice of adjusting variables. Further, the
outcome measure and any restriction to a subgroup also affect the
number of patients and events. These numbers are a key element
determining the statistical reliability of any analysis. Readers thus
need to understand which patients (and how many events) were
included in each analysis, and also which variables were used. For
all of these reasons, a standard format for reporting all analyses
performed would be extremely helpful and is strongly recom-
mended.
We developed a two-part study profile which has already been
used in a paper on the reporting of prognostic studies [20]. As
illustrated in the examples below, the first part gives details about
how the marker of interest was handled in the analysis and which
further variables were available. In addition, key information can
usefully be provided in this part about the patient population,
inclusion and exclusion criteria, and the number of eligible
patients and events for each outcome in the full data set. In the
first example (Table 2), the number and reasons for patients
excluded are given, but not the numbers for each reason. These
numbers can easily be given and would help readers to assess a
study.
As the patient population is often heterogeneous with regard to
stage of the disease, treatment and other factors, it is common
practice to assess the marker in several more homogeneous
subgroups of the population. Furthermore, several outcomes (for
example, DFS, distant DFS, or overall survival, OS) are usually
considered. Figures showing Kaplan-Meier estimates are often
presented for a univariable assessment, for a continuous marker
divided into subgroups. However, the results of further analyses
and details about variables in a multivariable model are often only
briefly summarized in the text or perhaps not mentioned at all.
(See Box 5 for discussion of the implications of selective reporting.)
To help the reader understand the multiplicity of analyses and
better assess the results, the second part of the proposed profile
gives an overview of all analyses. Nearly all reports of prognostic
marker studies include univariable, multivariable, and subgroup
analyses. Several multivariable analyses are often reported in
prognostic marker studies. It is critical to know which variables
were available in order to determine the most appropriate
multivariable analysis for a given study. Also, it is frequently
unclear which variables have been adjusted for in each analysis.
Often, some analyses and their results are mentioned in just one
sentence in the text (for example, ‘the effect of marker x was the
same in subgroup A’ or ‘the effect of marker x was unchanged
when adjusting for the three variables v1, v2 and v3’) and will only
be noticed by a careful reader. Further, it may not be obvious that
some analyses were based on only a small number of patients and
a handful of events.
Reporting of estimated effects from models and estimates of
survival curves often concentrate on DFS and results from OS are
less prominently shown. One reason may be the larger number of
DFS events, even though OS may be the more important
outcome. Reporting the number of deaths may reveal that the
effective sample size is very small. To assess the value of any
analysis it is important to know both the number of patients and
events (the effective sample size) for the outcome.
We attempt to illustrate the issues described above in relation to
two rather different studies. The study by Pfisterer et al. [157]
Figure 1. Example of a participant flow diagram [177].
doi:10.1371/journal.pmed.1001216.g001
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Table 2). As the disease has a very bad prognosis, the authors
decided to consider OS as the only outcome of interest. Part (a)
presents the information about the patients, treatments, and
variables studied. Part (b) gives an overview of all analyses with
numbers of patients and events, and the reader is guided to where
those results are presented in the report.
The study by Wadehra et al. [158] investigated the expression of
epithelial membrane protein-2 in patients with endometrial
adenocarcinoma (Table 3). In contrast to the first example, both
DFS and OS were investigated. Several features are immediately
apparent: the sample sizes for these two outcomes differ, only one
multivariable analysis was reported for each of the two outcomes,
and the marker of interest did not enter the final model for OS.
The profile thus gives reviewers, editors, and readers a greater
opportunity to evaluate what was done and whether anything
important is missing. Indeed, creating such a profile should be
helpful to authors too.
Because of the large variety of analyses that may be performed,
the profile for a specific study may need to differ in structure from
these examples. However, we propose that the key elements of the
profile, as shown in the two examples, be included. Wide adoption
of this presentation format would considerably aid the transparent
reporting of prognostic marker research and help to remedy the
widespread deficiencies that have been well documented.
The need for a study profile is supported by the difficulty we
encountered in finding published articles that presented all the
information to construct a profile. Also, a review of 50 articles in
cancer journals in 2006 to 2007 reporting tumor marker
prognostic studies found that typically only half of the REMARK
profile items were reported and these were often difficult to find
[20]. Half of the articles did not report the number of events for
any analyses or outcomes.
Item 13. Report distributions of basic demographic
characteristics (at least age and sex), standard (disease-
specific) prognostic variables, and tumor marker,
including numbers of missing values.
Examples
See Table 4 and Figure 2, and Figure 1 in [29].
Explanation
Inclusion and exclusion criteria (Item 2) describe the target
patient population. The group of patients included in a particular
study is a sample from that population. Distributions of basic
demographic variables and standard prognostic variables should
be reported to characterize the group of patients who were
actually studied. These demographic and standard prognostic
variables are often the variables to be considered for inclusion in
multivariable analyses (see Item 8). Distributions of age and sex
should routinely be reported. If available, racial or ethnic
distributions are sometimes helpful to report, as some markers
Table 2. Example of the REMARK profile illustrated using data from a study of ploidy in patients with advanced ovarian cancer
[157] (from [20]).
a) Patients, treatment and variables
Study and marker Remarks
Marker (If non-binary: how was
marker analyzed? continuous or
categorical. If categorical, how
were cutpoints determined?)
M=ploidy (diploid, aneuploid)
Further variables (variables
collected, variables available for
analysis, baseline variables,
patient and tumor variables)
v1=age, v2=histologic type, v3=grade, v4=residual tumor, v5=stage, v6=ascites
a, v7=estrogen
a, v8=progesterone
a,
v9=CA-125
a
Patients n Remarks
Assessed for eligibility 257 Disease: Advanced ovarian cancer, stage III and IV
Patient source: Surgery 1982 to 1990, University Hospital Freiburg
Sample source: Archived specimens available
Excluded 73 General exclusion criteria
b, non-standard therapy
b, coefficient of variation .7%
b
Included 184 Previously untreated.
Treatment: all had platinum based chemotherapy after surgery
With outcome events 139 Overall survival: death from any cause
b) Statistical analyses of survival outcomes
Analysis Patients Events Variables considered Results/remarks
A1: Univariable 184 139 M, v1 to v5 Table 2, Figure 1
A2: Multivariable 174 133 M, v1, v3 to v5 Table 3 [v2 omitted because many missing data; Backward
selection, see text]
A3: Effect for ploidy adjusted for v4 184 139 M, v4 Figure 2 [Based on result of A2]
A4: Interaction: ploidy and stage 175 133 M, v1, v2, v4, v5 See text
A5: Ploidy in stage subgroups
v5=III 128 88 M Figure 3
v5=IV 56 51 M Figure 4
aNot considered for survival outcome as these factors are not considered as ‘standard’ factors and/or number of missing values was relatively large;
bvalues not given in the paper.
doi:10.1371/journal.pmed.1001216.t002
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positive association between epidermal growth factor receptor gene
mutation and Asian ethnicity). For most types of cancers, there are
some standard clinical and pathologic prognostic variables (for
example, pathologic stage information including nodal status, tumor
size and presence of metastases, or clinical measures such as
performance status), and distributions of these variables should be
reported. The number of patients with missing values should be
reported for each variable as should the number of patients for whom
there are complete data on all variables or on those variables whose
effect on a survival outcome is assessed in a multivariable model.
If patients are a subsample from a randomized trial or large
defined cohort it is helpful to compare the characteristics of those
with and without tumor marker measurements to help judge the
generalizability of the findings.
A thorough description of the distribution of the marker of
interest should also be provided. The distribution may be
described by a frequency table or bar chart for categorical
variables or numerically by use of summary statistics such as mean,
median, percentiles, range, and standard deviation for continuous
variables. Figures such as histograms or boxplots are informative
for continuous variables. Presenting continuous data only in
categories is insufficient (see Box 4), but grouped data can be
presented in addition to the summary statistics.
Analysis and Presentation
Item 14. Show the relation of the marker to standard
prognostic variables.
Examples
See Tables 5, 6, and 7.
‘On analyzing the relationship between receptor data and the
above-mentioned prognostic factors, we found a significant
correlation between patient age and ER (ICC [immunocytochem-
istry], r=.46; DCC [dextran-coated charcoal], r=.43). While
tumors from patients #50 years old were ER positive in only 41%
(ICC) and 67% (DCC) of cases, patients .50 years had ER-
positive carcinomas in 77% (ICC) and 81% (DCC) of cases. In
addition, a weakly significant negative correlation was found
between the number of positive axillary nodes and ER (ICC,
r=218; DCC. r=2.15) and a weakly significant negative
correlation between tumor grade and ER (ICC, r=2.17) as well
as PR (ICC, r=2.24; DCC, r=2.14). No significant correlation
between steroid receptors and the remaining prognostic factors,
tumor size and histology, was found.’ [159]
Explanation
The association of the tumor marker with standard prognostic
variables should be described. A new marker is most useful if it
provides clinically important information beyond that given by
existing prognostic variables or indices, or it offers an advantage
over other markers because it is easier to measure or quantify.
Often a new marker has at least a modest association with some
other standard prognostic markers. In a multivariable model,
modest correlations between the marker value and other standard
variables in the model will influence the estimated effect of the
marker and increase its standard error. If there are very strong
correlations between two or more variables in a model (for
example, between age, estrogen and progesterone receptor in
breast cancer), effects estimated from the model can be very
unstable and difficult to interpret, requiring great care in model
building (see Item 10d). Further, if the marker has a very high
correlation with routinely available standard prognostic variables
that can be measured more easily, reproducibly, and inexpensive-
ly, it is unlikely to have clinical value either as a replacement for
the standard variables or as an adjunct to the standard variables.
Therefore, it is important to report the strength and nature of the
association between the marker and other variables. Additionally,
it is helpful to summarize the associations between the other
Box 5. Selective Reporting
Publication of the findings of only some of the research
that was done in a field will lead to bias when publication
choices are made with the knowledge of study findings.
Selection is mostly in relation to whether or not results
were statistically significant (P,0.05) or show a trend in
the favored direction. Selective reporting of studies, or
selective reporting of only some analyses within studies,
both lead to larger effects being seen in smaller studies,
and literature that is biased towards overestimating the
prognostic importance of tumor markers [204].
Evidence of biased non-publication of whole studies has
been accumulatingfor manyyears,but recentlyresearchhas
demonstrated evidence of additional within-study selective
reporting [205,206]. Empirical evidence of study publication
bias and within-study selective reporting primarily relates to
randomized controlled trials, but it is likely to be a major
concern for prognostic studies. Publication bias in prognos-
tic studies may be worse as many of these studies are based
on retrospective analysis of existing clinical databases.
Indeed, there is no indication that a particular marker or
marker-related hypothesis has been studied until and unless
itispublished.Areviewof1915articlesoncancerprognostic
markersfoundthatlessthan1.5%werefullynegative,inthat
they did not present any statistically significant prognostic
results [207]. A systematic review of studies of Bcl2 in non-
small cell lung cancer revealed that almost all the smaller
studies showed a statistically significant relationship be-
tween Bcl2 and risk of dying with large hazard ratios,
whereas the three large studies were all non-significant and
showed much smaller effects [208]. A review of the
prognostic importance of TP53 status in head and neck
cancer showed clearly that published studies had larger
effectsthanunpublished studies [17,209]. Suchstudiespoint
to the value of a register of biomarker studies [210].
Possible within-study selective reporting could take several
forms. For example, in cancer studies two principaloutcomes
are time to death (overall survival) and time to recurrence of
disease (that is, disease-free survival). Many studies report
only one of these outcomes. Although both unadjusted and
adjusted results are usually provided, some studies only
report unadjusted results [211]; in general they will be larger
than adjusted results. Similar concerns relate to selective
reporting of only some subgroup analyses performed.
Reports should include discussion of all analyses performed
and whether they were pre-planned (see Item 12). Often a
number of exploratory analyses are conducted. The explor-
atory nature should be clearly stated. Reasons for these
analysesandresultscan besummarizedin afewsentences.A
further issue is that some results are only reported partially,
for example, solely as ‘not significant’, preventing that study
from contributing to a subsequent meta-analysis.
Problems that can arise from selective reporting are
discussed in relation to clinical endpoints, the flow of
patients through the study and reporting of events and
estimated effects for all variables in Items 7, 12, and 16,
respectively. Obviously, selective reporting is an important
impediment to reliable assessment of a marker according
to evidence based medicine criteria [19,212–214].
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ing combinations of standard variables are being considered.
Graphical displays can be particularly helpful in conveying the
nature of associations between the marker and other variables. For
two continuous variables (for example, a continuous marker versus
a continuous standard variable or prognostic index), scatterplots
are most informative, and these may be accompanied by summary
measures such as correlations. The study report should include a
summary description of the findings of these association assess-
ments. Often the tumor marker and other standard variables are a
mix of continuous and categorical measurements. Displays such as
boxplots, dotplots, or histograms of the continuous measures for
each of the levels or combinations of the categorical variables can
be informative. Categorizing continuous variables should be
avoided (see Box 4). If all variables are categorical, tables showing
cross-classifications of cases by categories of the marker and
categories of each of the standard variables are useful. Such
descriptive analyses are also helpful for interpretation of multi-
variable models and assessment of the stability of those models.
In order for a marker to provide some information independent
of the values of existing variables, it must show variation when the
other variables are held fixed. That variation can take different
forms. The marker might show variation within all possible ranges
of the existing variables, or it might show variation within some
ranges of existing variables but not within others. This informa-
tion, together with an assessment of how the variation in the
marker correlates with clinical outcome (see Items 15–17), will
suggest those patients for whom the new marker might provide
clinically useful new information.
Item 15. Present univariable analyses showing the
relation between the marker and outcome, with the
estimated effect (for example, hazard ratio and survival
probability). Preferably provide similar analyses for all
other variables being analyzed. For the effect of a tumor
marker on a time-to-event outcome, a Kaplan-Meier
plot is recommended.
Examples
See Figure 3 and Table 8.
Explanation
A marker’s simple association with outcome should be shown
first, without adjustment for other clinical or pathologic charac-
teristics to indicate its prognostic strength before allowance is
made for other variables.
For a binary clinical endpoint (for example, tumor response or
disease progression within one year) with a categorical marker,
authors can report the observed outcome probabilities for each
category of marker value. Sparse categories (those with few
patients) may have been combined in the initial data analysis (see
Item 10a and Box 4). For a continuous marker it is informative to
present a summary of marker values (as in Item 13) separately for
those patients with and without the endpoint. Alternatively, a plot
of log odds ratio (or a similar measure) as a function of the
continuous marker value could be presented. A statistical test of
the difference (for example, chi-square test, t-test, or test for trend)
may accompany the summary description of the association of the
marker with the outcome.
For a time-to-event outcome, the relation between a categorical
marker and outcome can be assessed by a statistical test such as the
logrank test (using the test for trend for ordered categories with
more than two groups) [160]. Additionally, a hazard ratio estimate
(for example, as derived from a Cox proportional hazards
regression model) or some other summary estimate of the
Table 3. Example of the REMARK profile illustrated using data from a study of expression of epithelial membrane protein-2 in
patients with endometrial adenocarcinoma [158].
a) Patients, treatment and variables
136 Patients with endometrial adenocarcinoma assessed for eligibility, 37 excluded (33 no informative immune histochemistry, 4 without clinical information)
99 Patients included, stages IA to IVB
Formalin fixed, paraffin embedded endometrial tissue samples, Department of Pathology, UCLA Los Angeles, USA
Marker (and how was the marker handled in analysis?) M=epithelial membrane protein-2
Immunoreactive score obtained by multiplying subscores for intensity (0 to 3+) and distribution of
immunoreactivity (0 to 4+) grouped as negative (score 0), weak (1 to 3) or moderate-to-strong (4 to
12)
Outcomes: DFS (97 patients, 42 events), OS (99 patients, 32 events)
Further variables: v1=age, v2=ER, v3=PR, v4=vascular invasion, v5=stage, v6=histology, v7=grade
b) Statistical analyses of survival outcomes
DFS OS
Aim Patients Events Patients Events
Variables
considered Results/remarks
A1: Univariable 97 42 99 32 M, v1-v7 Figure 3, Figure 4, Table 2, Table 3
DFS: except v1 all significant
OS: all significant
A2: Multivariable 97 42 99 32 DFS: M, v2-v7 Table 4, Table 5
OS: M, v1-v7 In multivariable analysis: all significant in
A1, then stepwise selection
Variables in final models: DFS: M, v5, v6; OS:
v4, v6, v7 (M is not included)
DFS: disease-free survival; ER: estrogen receptor; M: epithelial protein; PR: progesterone receptor; OS: overall survival.
doi:10.1371/journal.pmed.1001216.t003
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Precision and uncertainty of the estimates should be indicated, for
example by providing confidence intervals. P values may also be
presented. For continuous markers, one can investigate the
influence of the marker on outcome without having to categorize
the marker (see Box 4). If any categorizations or transformations
Table 4. Example of tabular reporting of patient characteristics [180].
Patients
All CK-19 mRNA + CK-19 mRNA 2
Characteristic Number % Number % Number % P
Patients enrolled 444 100 181 40.8 263 59.2
Age, years
Median 54 54 55
Range 26 to 78 26 to 74 30 to 78 0.752
Menopausal status 0.075
Premenopausal 191 43 87 45.5 104 54.5
Postmenopausal 253 57 94 37.2 159 62.8
Tumor size 0.648
T1 157 35.4 61 38.9 96 61.1
T2 251 56.5 103 41 148 59
T3 36 8.1 17 47.2 19 52.8
Histology grade 0.316
I/II 204 46 87 42.6 117 57.4
III 191 43 72 37.7 119 62.3
Unknown 49 11 22 27
Infiltrated axillary lymph nodes 0.538
0 163 36.7 61 37.4 102 62.6
1 to 3 122 27.5 53 43.5 69 56.5
$4 159 35.8 67 42.1 92 57.9
ER 0.779
Negative 175 39.4 71 40.6 104 59.4
Positive 260 58.6 109 41.9 151 58.1
Unknown 9 2 1 8
PR 0.126
Negative 234 52.7 89 38 145 62
Positive 201 45.3 91 45.3 110 54.7
Unknown 9 2 1 8
HER2 0.897
0, 1+ 290 65.3 122 42.1 168 57.9
2+ 53 11.9 21 39.6 32 60.4
3+ by IHC 88 19.8 35 39.8 53 60.2
Unknown 13 3 3 10
Adjuvant chemotherapy 0.425
CMF 43 9.7 14 32.6 29 67.4
FEC 209 47.1 84 40.2 125 59.8
EC-T 192 43.2 83 43.2 109 56.8
Surgery 0.478
L 310 69.8 123 39.7 187 60.3
M 134 30.2 58 43.3 76 56.7
Radiotherapy 0.799
No 81 18.2 32 39.5 49 60.5
Yes 363 81.8 149 41 214 59
CK-19: cytokeratin-19; CMF: cyclophosphamide, methotrexate, fluorouracil; EC-T: epirubicin, cyclophosphamide, docetaxel; ER: estrogen receptor; FEC: fluorouracil,
epirubicin, cyclophosphamide; IHC: immunohistochemistry; L: lumpectomy; M: mastectomy; PR: progesterone receptor.
doi:10.1371/journal.pmed.1001216.t004
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for an association estimate to be interpretable (see Item 11).
Similar analyses are useful for showing the relation to outcome
of all other variables being assessed. Such analyses allow
confirmation of expected prognostic relations. Results differing
from expectations may point to some problems in the study, such
as biased patient selection or measurement techniques. Univari-
able measures of association with outcome can sometimes be
presented conveniently along with the distributions of each
variable (see Item 13) in a single table.
For a time-to-event outcome, a plot of Kaplan-Meier survival
curves is recommended [161,162], with one curve shown for each
category of marker value (two curves for a binary marker). The
number of patients at risk should be provided for selected time
points. To plot Kaplan-Meier estimates for continuous markers or
markers with many categories, the marker values are typically
combined into a few groups. For continuous markers, the groups
are often constructed to contain equal numbers of patients (for
example, based on tertiles or quartiles) or the groups may be
defined using cutpoints established in a previous study. Regardless
Table 5. Relation between marker (serum chromogranin A) and patient characteristics [181] (note that missing data were not
indicated).
Serum CgA levels, ng/mL
Number Median Q1 to Q3 Minimum to maximum P
Subjects
Controls 50 77.4 57.7 to 99.9 28.2 to 196.3
NSCLC patients 88 70.4 37.9 to 114.6 8.7 to 723.8 0.337
Histotype
Adenocarcinoma 22 59.2 35.2 to 85.6 14.8 to 151.2
Squamous 27 80.0 41.0 to 128.6 14.7 to 386.8
Large cell 10 82.1 33.7 to 124.0 11.4 to 217.9 0.465
ECOG PS
0 16 37.7 27.2 to 68.6 8.7 to 103.1
1 59 76.3 43.6 to 119.2 13.9 to 429.7
$2 13 102.8 55.8 to 259.4 32.1 to 723.8 0.0005
Stage
IIIB 29 44.9 29.2 to 85.6 13.9 to 259.4
IV 59 82.5 47.1 to 119.2 8.7 to 723.8 0.043
CgA: chromogranin A; ECOG PS: Eastern Cooperative Oncology Group performance status; NSCLC: non-small cell lung cancer; Q1 to Q3: interquartile range.
doi:10.1371/journal.pmed.1001216.t005
Figure 2. Frequency distribution of Steroid Receptor RNA Activator Protein (SRAP) H-scores in 372 breast tumors, showing median
of 76.67 used to delineate low and high subgroups [179] (for a secondary example see Figure 1 in [29]).
doi:10.1371/journal.pmed.1001216.g002
PLoS Medicine | www.plosmedicine.org 22 May 2012 | Volume 9 | Issue 5 | e1001216Table 7. Relation between patient characteristics and steroid receptor status by immunocytochemistry and dextran-coated
charcoal [159].
Parameter n (%) Estrogen receptor positive Progesterone receptor positive
ICC (%) DCC (%) ICC (%) DCC (%)
Axillary node status (n=241)
N0 120 (49.8) 88 (73.3) 98 (81.7) 83 (69.1) 93 (77.5)
N+ 121 (50.2) 75 (62.0) 89 (73.6) 75 (61.9) 94 (77.7)
Tumor size (cm) (n=229
a)
,2 86 (37.6) 59 (68.6) 69 (80.2) 60 (69.8) 69 (80.2)
2–5 128 (55.9) 88 (68.8) 101 (78.9) 84 (65.6) 100 (78.1)
.5 15 (6.6) 8 (53.3) 9 (60.0) 8 (53.3) 9 (60.0)
Tumor histology (n=241)
Invasive ductal 171 (71.0) 120 (70.2) 136 (79.5) 119 (69.6) 136 (79.5)
Lobular 38 (15.8) 26 (68.4) 31 (81.6) 22 (57.9) 30 (78.9)
Other
b 32 (13.2) 17 (53.1) 20 (62.5) 17 (53.1) 21 (65.6)
Tumor grade (n=217)
c
1+2 142 (65.4) 106 (74.7) 118 (83.1) 104 (73.2) 119 (83.8)
3 75 (34.6) 41 (54.7) 52 (69.3) 36 (48.0) 53 (70.7)
Patient age (y) (n=241)
#50 63 (26.1) 26 (41.3) 42 (66.7) 45 (71.4) 54 (85.7)
.50 178 (73.9) 137 (77.0) 145 (81.5) 113 (63.5) 133 (74.7)
aNo information available on tumor size in 12 cases;
bmucinous, tubular or medullary;
cno information available on tumor grade in 24 cases.
DCC: dextran-coated charcoal; ICC: immunocytochemistry.
doi:10.1371/journal.pmed.1001216.t007
Table 6. Relation between marker (E-Cadherin) and patient characteristics [182].
Variable E-Cadherin staining index
a
Low High
Number of patients % Number of patients %
Histologic type
Endometrioid
b 135 53 120 47
Clear-cell or serous papillary 24 83 5 17
FIGO grade
1 2 54 9 2 65 1
2 6 35 1 6 14 9
3 7 16 5 3 83 5
Vascular invasion
0 or 1 vessel 94 52 88 48
$2 vessels 65 64 37 36
Myometrial infiltration
c,%
,50 77 51 74 49
$50 67 66 35 34
FIGO stage
d
I or II 120 53 108 47
III or IV 39 71 16 29
aResults available in 284 patients.
bAdenosquamous and adenoacanthoma are included.
cInformation available in 253 patients (E-cadherin) and 255 patients (beta-catenin).
dData missing in one patient.
doi:10.1371/journal.pmed.1001216.t006
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reported. Choosing groups based on maximizing association with
outcome is dangerous (see Item 11 and Box 4). It can also be
helpful to report estimates of survival probabilities at a few specific
time points of interest along with corresponding confidence
intervals (for example, 95%) for each marker category.
Univariable measures of association of the marker with outcome
and differences between Kaplan-Meier curves might be heavily
Figure 3. Kaplan-Meier plot for disease-free survival comparing patients with HU177 concentrations above and below the median
value. [178]
doi:10.1371/journal.pmed.1001216.g003
Table 8. Univariable analyses of relation of UBE2C protein and standard variables to overall survival in 92 women with node-
positive breast cancer [183].
Variable HR 95% CI P
Age 1.06 1.01 to 1.12 0.026
Histology (IDC versus others) 0.48 0.18 to 1.27 0.139
Histological size (,20 mm versus $20 mm) 2.97 0.68 to 12.94 0.147
SBR (I versus II versus III) 3.97 1.67 to 9.47 0.001
Positive nodes (1 versus 2 versus 3 versus .3) 1.81 1.19 to 274 0.005
Estrogen receptor (+ versus 2) 0.18 0.07 to 0.47 ,0.001
Progesterone receptor (+ versus 2) 0.51 0.19 to 1.37 0.182
IHC Ki-67 (,11% versus $11%) 8.59 1.14 to 64.57 0.037
IHC UBE2C (,11% versus $11%) 7.14 1.64 to 31.11 0.009
NPI scores (1 versus 2 versus 3) 4.48 1.74 to 11.52 0.002
CI: confidence interval; IDC: infiltrating ductal carcinoma; IHC: immunohistochemistry; HR: hazard ratio; NPI: Nottingham Prognostic Index; SBR: Scarff-Bloom-Richardson.
doi:10.1371/journal.pmed.1001216.t008
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the marker. However, those analyses are still useful to report as
they provide a baseline against which to compare measures of
association that are adjusted for other variables (multivariable
analysis - see Item 16). For this reason it is helpful to present
univariable regression analyses as they allow direct comparison of
the unadjusted and adjusted hazard ratios.
Item 16. For key multivariable analyses, report
estimated effects (for example, hazard ratio) with
confidence intervals for the marker and, at least for
the final model, all other variables in the model.
Examples
See Tables 9 and 10.
Explanation
Since a tumor’s biological characteristics are not controllable
experimentally like treatment in a RCT, a study examining the
prognostic value of a tumor marker is subject to the usual
challenges inherent in analysis of observational studies, such as
adjustment for the effect of potential confounding factors. Some of
these other factors are standard variables that are generally
accepted as being related to prognosis while others might be
candidate variables that are available but have unknown
prognostic significance or uncertain relation to the marker of
interest. Any of these variables might be considered for inclusion in
multivariable models that are developed during the course of the
data analysis (see Items 12 and 17). Certain of these multivariable
models are of particular importance and the results associated with
these models should be reported in more detail.
Often the multivariable data analysis involves a model building
process that begins with what we will designate as the ‘full model’
and, after several data-dependent modeling steps, may result in
identification of a ‘final model’. The full model is a model
containing all the available candidate variables (see Item 8), often
depending on decisions from the initial data analysis step
considering missing values, distribution of the variables (for
example, collapsing of small categories), and other aspects of the
data (see Item 10a). Usually the full model contains too many
variables to be readily interpretable, but it may serve as the
starting point for variable selection, if done, using a method such
as backward elimination (see Item 10d) [66]. The final model,
which is a more parsimonious model obtained at the end of the
variable selection and modeling process, will provide estimates of
adjusted effects that are more interpretable, but the effects may
also be biased to appear stronger than they actually are due to the
variable selection process that had been used. The ‘standardized
model’ (for explanation see Item 17) is another important
multivariable model that should be examined in prognostic
studies. However, its components are determined on the basis of
clinical and pathologic considerations rather than through data-
dependent model building, and hence it is discussed separately.
The REMARK profile (see Item 12) illustrates which analyses
were performed.
As discussed for univariable models (see Item 15), precision and
significance of estimated effects should be indicated by providing
confidence intervals and P values. At least for the final model these
measures should be provided for all variables in the model. If
multivariable models are also developed for key patient subgroups
(for example, separate models for men and women, see Box 1),
effect estimates, confidence intervals, and P values should be
provided for all variables in the main subgroup models. For
additional multivariable models that do not differ substantially
from the main models reported in detail, it may be sufficient to
give effect estimates with confidence intervals for the marker of
interest only or to summarize results in simple statements. For
example, such models might have been used in sensitivity analyses
in which a standard variable was eliminated or in which different
assumptions were used (see Items 10g and 18).
In a review of 50 studies published in high impact cancer
journals in 2006 to 2007, more than one multivariable analysis was
reported in 30 of them (60%) [20]. For the primary marker, an
effect estimate with confidence interval from the multivariable
model was reported in 84%, but only 66% of the papers presented
effect estimates for all variables in the final model.
Item 17. Among reported results, provide estimated
effects with confidence intervals from an analysis in
which the marker and standard prognostic variables are
included, regardless of their statistical significance.
Examples
‘When all standard prognostic clinical variables were included
as co-variables in a Cox proportional hazards model, there was
again no evidence that these two markers were significantly
associated with OS (HR=0.99, 95% CI 0.79–1.25 and P=0.9 for
TS [thymidylate synthase] and HR=0.98, 95% CI 0.78–1.23 and
P=0.8 for p53).’ [76]
See Table 11.
Explanation
For many clinical situations one can identify some standard
variables that have previously been demonstrated to have
prognostic value and are generally measured for most patients
having the particular diagnosis. Although there may be some
difference from study to study, there may be a core group of
variables that are examined in most studies or are recommended
in clinical consensus guidelines. Typical standard variables include
disease stage and its constituent elements, such as tumor size and
nodal status, and sometimes patient demographic variables such as
Table 9. Multivariable Cox regression analysis of relapse-free
survival in patients with primary breast cancer showing the
impact of adding the marker (PMN-E) to a base model of
recognized prognostic variables [59].
Factor HR (95% CI) P
Base model
Age and menopausal status combined 0.005
Age premenopausal
a 0.68 (0.55 to 0.85)
Age postmenopausal
a 0.96 (0.84 to 1.09)
Post- versus premenopausal 1.83 (1.27 to 2.46)
Tumor size ,0.001
2 cm to 5 cm versus #2 cm 1.69 (1.36 to 2.10)
.5 cm versus #2 cm 2.31 (1.73 to 3.10)
Nodal status ,0.001
N1–3 versus N0 1.66 (1.30 to 2.11)
N.3 versus N0 2.75 (2.18 to 3.47)
ER (positive versus negative)
b 0.87 (0.68 to 1.11) 0.25
PgR (positive versus negative)
b 0.76 (0.61 to 0.95) 0.02
Additions to base model
+PMN-E (high versus low)
c 1.45 (1.10 to 1.89) 0.01
+PMN-E (continuous)
d 1.06 (0.98 to 1.14) 0.13
aAge in decades for pre- and postmenopausal patients;
bPositive, $10 fmol/mg protein; negative ,10 ng/mg protein;
cHigh, .36.4 ng/mg protein; low, #36.4 ng/mg protein;
dLog-transformed variable.
CI: confidence interval; ER: estrogen receptor; PgR: progesterone receptor.
doi:10.1371/journal.pmed.1001216.t009
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eligibility for inclusion in a study (see Item 2). It is important to
evaluate whether the new marker maintains some association with
clinical outcome after accounting for these standard prognostic
variables. There should be discussion and explanation of how
these standard variables have been selected. Sometimes these
variables may already belong to an established multivariable score
and this should also be referenced [163].
Evaluation of a marker’s effect adjusted for standard variables is
generally accomplished by examining what we will call the
‘standardized model’, which includes the marker of interest as well
as all of the standard variables, regardless of their statistical
significance. Different treatments may be accounted for by
indicator variables or by stratification. Irrespective of what other
multivariable models are considered, the results of fitting this
standardized model should be explicitly reported as it facilitates
the comparison of estimated effects of the marker across studies.
This model should be clearly distinguished from other multivar-
iable models that may have been fit during the course of the data
analysis (see Item 12), particularly the full model and the final
model (see Item 16).
Comparison of the effect estimates from the standardized model
to univariable effects (see Item 15) and to effects estimated from
other key multivariable analyses (see Item 16) will provide a clearer
picture of whether the marker contributes prognostic information
beyond that provided by existing variables. Therefore, it is
important to present the standardized model including estimated
effects for the marker and each of the standard variables and
measures of their precision and significance as indicated by
confidence intervals and P values. When the goal is to build a
prognostic model and quantify how a model with standard
prognostic variables is improved by incorporating the new marker
into the model, a measure such as change in predictive accuracy
can be presented [164,165] (see also Item 10d).
Item 18. If done, report results of further investiga-
tions, such as checking assumptions, sensitivity analy-
ses, and internal validation.
Examples
‘Estimated effects were similar in the model without stratifica-
tion (data not shown). In a sensitivity analysis on the complete case
population (128 patients, 29 deaths), number of arteries and
angioinvasion were still the strongest prognostic factors.’ [166]
‘No significant deviation from the proportional-hazard assump-
tion could be found by evaluating an interaction term of the
change variables and the logarithm of time. Furthermore, the
interaction between the change during the first and the change
during the second month was not significant.’ [167]
‘A more detailed investigation with the multivariable fractional
polynomial approach did not reveal any strong indication of a
nonlinear effect and selected the same variables.’ [136]
Explanation
Results of many prognostic studies rely on the validity of the
statistical models used in the analysis, and inherent in any model
are certain assumptions (for example, proportional hazards, linear
effects of covariates, and missing data mechanisms). Prognostic
analysis results will have greater credibility if arguments can be
made that the modeling assumptions are likely to be justifiable or
that the results are not unduly sensitive to certain assumptions.
The report should mention the results obtained from any
additional analyses that were performed or diagnostic plots that
were examined for the purpose of checking assumptions or
demonstrating robustness of results (see Item 10g and Box 4). It
will often be impractical or unnecessary to present detailed
Table 10. Multivariable Cox regression models of overall survival for subgroups of size of residual postoperative tumor [184].
Parameter No residual postoperative tumor Residual tumor 1 mm to 10 mm Residual tumor .10 mm
HR 95% CI P HR 95% CI P HR 95% CI P
Age (10 y) 1.24 (1.11 to 1.37) ,0.0001 1.12 (1.03 to 1.21) 0.0068 1.10 (1.02 to 1.18) 0.0103
ECOG 2 versus 0–1 1.78 (1.24 to 2.55) 0.0016 1.47 (1.16 to 1.87) 0.0013 1.22 (1.01 to 1.47) 0.0365
FIGO IIIC-IV versus IIB-IIIB 1.41 (1.13 to 1.75) 0.0024 1.49 (1.20 to 1.85) 0.0003 1.48 (1.16 to 1.90) 0.0019
Grading G2/3 versus G1 2.19 (1.45 to 3.30) 0.0002 1.57 (1.00 to 2.46) 0.0524 1.46 (0.99 to 2.15) 0.0569
Endometrioid versus serous 0.84 (0.61 to 1.16) 0.2867 0.95 (0.69 to 1.30) 0.7328 0.97 (0.73 to 1.29) 0.8355
Mucinous versus serous 1.97 (1.26 to 3.08) 0.0028 2.76 (1.90 to 4.02) ,0.0001 2.29 (1.70 to 3.10) ,0.0001
Ascites, yes versus no 1.92 (1.52 to 2.41) ,0.0001 1.18 (0.96 to 1.45) 0.1178 1.31 (1.10 to 1.56) 0.0023
CI: confidence interval; HR: hazard ratio; ECOG: Eastern Cooperative Oncology Group; FIGO: Fe ´de ´ration Internationale de Gyne ´cologie et d’Obste ´trique.
doi:10.1371/journal.pmed.1001216.t010
Table 11. Prognostic values of several factors in a
multivariable analysis of overall survival for 175 patients with
ovarian carcinoma Stage III/IV [157].
Factor HR 95% CI P
Age
#60 1.00 — 0.051
.60 1.46 1.00 to 2.13
Stage
III 1.00 — 0.33
IV 1.20 0.83 to 1.74
Grade
1 1.00 — 0.11
2+3 1.62 0.89 to 2.94
Residual tumor
#5 mm 1.00 — ,0.001
.5 mm 3.95 1.86 to 8.37
Ploidy
diploid 1.00 — 0.93
aneuploid 0.98 0.67 to 1.44
n=175, number of events=133. CI: confidence interval; HR: hazard ratio.
doi:10.1371/journal.pmed.1001216.t011
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should be stated. For example, a statement that a smoothed plot of
martingale residuals against a covariate exhibited a linear trend
would provide support for inclusion of the covariate as a linear
term in a Cox proportional hazards regression model; a statement
that covariates were checked for possible time-varying effects in a
Cox regression model but no significant effect seemed to be
present would provide support for the assumption of proportional
hazards. Results of assessments for differential marker effects
across subgroups or other types of interactions should be reported
(see Box 1). Stability analyses, for example, by using the bootstrap
[147,168], and conducting assessments including, but not limited
to, those mentioned above (see Item 10g) will provide supporting
evidence for the appropriateness of final model(s) that provide the
basis for the conclusions of the study [99,133].
In some situations, modeling assumptions cannot be empirically
verified, and the only recourse may be to demonstrate by
sensitivity analyses whether a reasonable range of alternative
assumptions still lead to similar conclusions as those reported for
the main analysis. For example, this problem is routinely
encountered when applying missing data imputation methods
[128,130] (see also Box 2). Because true missing data mechanisms
are usually unknown, it is recommended that results of any
alternative analyses (including complete case analysis) performed
under different assumptions about the missing data mechanism
(missing completely at random, missing at random, or missing not
at random) be reported so that the amount the results would
change can be assessed.
If either internal validation analyses or external validation
studies have been performed (see Item 10 h), the results of those
analyses should be described, regardless of the findings. Successful
validations greatly improve the chances that the study findings are
real.
Discussion
Item 19. Interpret the results in the context of the
pre-specified hypotheses and other relevant studies;
include a discussion of the limitations of the study.
Examples
‘We evaluated the prognostic significance of three VEGF SNPs
in a large cohort of patients with esophageal cancer. In
multivariate analysis, we showed that the heterozygous and
homozygous variant genotype of VEGF 936C/T conferred an
improved OS compared with the homozygous wild-type genotype
… Although this is the first study to evaluate VEGF SNPs in
esophageal cancer, two prior gastric cancer studies reported
conflicting results … There are limitations to this study. Although
others have correlated these VEGF SNPs with plasma VEGF
levels, due to the lack of available tissue samples, we were unable
to correlate VEGF genotype with VEGF mRNA or protein
expression within tumors … Secondly, the sample size of 361 is
very large for esophageal cancer but is only average for all studies
evaluating VEGF polymorphisms and cancer outcomes (median
sample size, 413; range, 100–1193). Finally, we used a candidate
polymorphism approach, which allows us to compare with studies
of other disease sites and focuses on functional variants, but
therefore will not evaluate the entirety of polymorphic variation
across this gene.’ [169]
‘Our data demonstrate that COX-2 expression is associated
with larger tumors, younger patient age, and generally more
aggressive breast cancer. These findings are consistent with several
other studies that have shown COX-2 expression to be associated
with more aggressive disease. Studies evaluating COX-2 expres-
sion as it relates to breast cancer aggressiveness and outcome are
summarized in Table 4.’ [170]
Explanation
The discussion is the appropriate section for authors to interpret
the data and suggest further research that might be needed. The
section should begin by briefly restating the purpose of the study
and recalling any pre-specified hypotheses. A simple summary of
the major findings should follow. This allows the reader to assess if
the study met its goals and to evaluate the evidence. A clear
distinction should be made between conclusions based on pre-
specified hypotheses and hypotheses suggested during the course of
the data analysis.
The authors should critically evaluate the reported results. This
evaluation should include an acknowledgment of any biases or
inconsistencies in the data, limitations of the assay methods, or
limitations of the design or data analysis methods. For example,
the study may have been underpowered, it may have been limited
to only tumors of sufficiently large size, the assay might be lacking
in reproducibility, important standard variables may have not
been available (for example, tumor grade in breast cancer), and
there may have been a large amount of missing data requiring
certain assumptions to be made in the analyses. If there are strong
biologically plausible subgroup effects, the discussion should
review how the prognostic value of the marker varies across those
subgroups. A thorough and open discussion will maximize the
value of the study results to the broader community, regardless of
whether the study results are as the investigators had hoped at the
initiation of their study. This discussion should include the authors’
assessment of whether the results of the study are generalizable to
other populations not studied in the current report. Any
unexpected findings should be identified. Even disappointing or
unexpected findings can yield important insights.
Following the summary, there should be a discussion of how the
results from the study integrate into the existing body of evidence.
It is helpful to include an explanation for the choice of references
cited (for example, only large studies or only studies in a similar
patient population) to allow the reader to evaluate whether
selective citation of references has influenced the interpretation of
the results. If a systematic review was conducted, it should be
described. (If the review was performed prior to initiation of the
study, its description may fit better in Item 1.) Authors should
comment on whether the results are consistent with, or differ from,
the general tendency in previous studies and offer potential
explanations for differences.
Item 20. Discuss implications for future research and
clinical value.
Example
‘The association of SMAD4 gene inactivation with poorer
prognosis and an increased propensity to metastasize has direct
clinical implications. Some patients with pancreatic cancer have
‘‘borderline’’ resectable tumors - they have resectable pancreatic
head cancers that are at high risk for a margin-positive resection.
Whereas further work is needed, our results, combined with those
previously reported in the literature, suggest that patients with
borderline resectable pancreatic cancers and SMAD4 gene
inactivation might be spared the risk of surgery because their
cancer is more likely to metastasize, whereas patients with
borderline resectable pancreatic cancers and intact SMAD4 may
benefit from the local control provided by neoadjuvant therapy
and surgical resection.’ [171]
Explanation
The rationale for studying any marker, prognostic or otherwise,
is to gain relevant information about the biology of the disease, to
find new tools to aid in clinical decision-making, or to develop new
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between a marker and an outcome may be encouraging, but in the
long term the difference in outcome should have clinically
important implications for patient care. If a prognostic marker
does not provide added value to existing prognostic information, it
may nevertheless be useful if it can be assessed more easily, at
lower cost, or measured more reproducibly than markers currently
used to provide clinically meaningful information.
In some cases, the results of a study will suggest that a marker
has some promise for clinical value, but a firm conclusion cannot
be drawn due to insufficient information. It is helpful in the
discussion of future research plans to specifically identify
information that is still lacking or inadequate. For example,
further studies might need to be conducted in expanded patient
populations or different patient subsets. Contemporary patient
populations diagnosed and staged using updated methods and
receiving more modern therapies and supportive care might need
to be studied. Further research studies may be required to resolve
differences in the performance of the marker noted in the
literature. The assay method might need refinement to improve its
robustness and accuracy before it is ready to be used in routine
clinical settings.
Ultimately, the goal of the research is to provide a tool of
clinically meaningful value to improve patient outcomes. The
discussion needs to provide a clear understanding of what the
current study has achieved toward that goal and what steps
remain.
Final Comments
Physicians seek information about tumor markers to inform
therapeutic decisions for individual patients. The availability of a
marker that can distinguish subsets of patients may also influence
the design of clinical trials. In order for information about the
utility of tumor markers to be appropriately evaluated, the
methods used to study the markers and the results generated
must be fully reported. The REMARK recommendations were
designed to help authors ensure that reports of their tumor marker
studies contain the information that readers need. Good reporting
reveals the strengths and weaknesses of a study and facilitates
sound interpretation and application of study results. The
REMARK recommendations may also aid in planning new
studies, and may be helpful for peer reviewers and editors in their
evaluation of manuscripts.
It was always our intention to supplement the checklist
publication [1–7] with a long explanatory paper, as has been
done for CONSORT, STROBE, and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement, for example [9–11,172]. Following the same model as
those articles, in this paper we have provided extensive discussion
of each item in the REMARK checklist, providing the rationale
and including illustrative examples of good reporting. Where
possible we have referred to relevant empirical evidence from
reviews of publications. We have also included several boxes to
provide additional discussion of some key aspects of prognostic
studies.
Although we have primarily focused on studies of single
prognostic markers, most of the recommendations apply equally
to other types of prognostic studies, including studies of multiple
markers, studies to predict response to treatment, and studies to
develop prognostic models. The REMARK recommendations
offer criteria against which to judge the completeness of reporting
of marker studies. We hope that improvements will be seen over
time, but as yet reviews have shown that incomplete reporting is
regrettably common [15,18,20,21,173]. We believe that the
REMARK recommendations should be useful in specialties other
than cancer, and there are already examples that this is so
[21,174–176].
REMARK is not intended to dictate standards for the quality of
research and it should not be used as such. However, it can be a
useful tool to help assemble the information needed in order to
assess the quality and relevance of research.
Reporting recommendations should change as necessary to
reflect new empirical evidence and changes in our understanding
of which aspects of research are important. We intend to monitor
the literature for new evidence and critical comments in the
expectation that the checklist will be updated in the future.
Several cancer journals ask authors to follow the REMARK
recommendations in their instructions to authors; we encourage
more journals to follow this example. Up-to-date information on
REMARK and numerous other reporting guidelines can be found
on the website of the EQUATOR Network (http://www.equator-
network.org).
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